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The Swedish model for contraceptive counselling is well developed with easy access from 
different clinical settings and extensive subsidies for young women. Sweden is a high income 
country and educational levels among citizens is normally high or at least moderate. Despite 
this, many Swedish women have an unmet need for contraception or rely on user dependent 
contraceptive methods resulting in high rates of unintended pregnancies and abortions. What 
are the underlying reasons to this “failure” from a structural point of view? Can something be 
done to increase knowledge about contraceptive methods among healthcare providers and 
women. What adjustments need to be undertaken to better meet the needs of women with 
regard to contraceptive use? How do we reach women with low levels of education?  
The urge to find answers to these questions is the basis for the research in this thesis.  
In a world were women need contraception to control for mistimed or unwanted pregnancies 
for a long period of time, we need to provide evidence-based contraceptive counselling. 
There is evidence “out there” that could improve the quality of care and enhance women’s 
ability to make an informed decision about contraceptive use. In this thesis, the research 
questions spring from this evidence and aims to evaluate methods to achieve better sexual 












BACKGROUND Unintended pregnancies are an inexhaustible source to life-changing 
decisions and events for individuals and result in enormous costs for societies having to deal 
with maternal health services, deliveries, hospital care and abortions. Unmet need of 
contraception is a contributing factor to unintended pregnancies. Women who rely on user-
dependent contraceptive methods experience higher failure rates. Increasing uptake of 
LARCs has proven to reduce unintended pregnancies and abortions, especially among young 
women. Several opportunities to counsel women about the most effective contraceptive 
methods are not accurately seized, such as when in need of emergency contraception, during 
regular contraceptive counselling and after induced abortion. Swedish women have the 
highest number of induced abortions among countries with robust statistics, and Sweden has 
the highest number of teenage abortions among Nordic countries. Improving access to facts-
based knowledge during contraceptive counselling, and by finding effective methods for pain 
management with intrauterine device insertion could increase uptake of the most effective 
contraceptive methods—long-acting reversible contraception. 
AIM This thesis includes original research within three subfields that all represent 
opportunities for provision of effective contraception. The thesis aims to find pathways to 
increase uptake of LARC by interventions used to improve the quality of care from both a 
healthcare provider's and a patient's perspective. 
METHODS Study I was an observational cohort study conducted at one reproductive health 
clinic in Stockholm, Sweden. This study aimed to compare use of an effective contraceptive 
method following copper-intrauterine device insertion for emergency contraception or use of 
an emergency contraceptive pill consisting of ulipristal-acetate. Study II was a double-
blinded, randomized, placebo-controlled trial conducted at one youth clinic and one 
reproductive health clinic in Stockholm. The aim was to investigate pain reduction with 
intrauterine device insertion among nulliparous women randomized to intrauterine instillation 
of either 1% mepivacaine (intervention) or 9% sodium-chloride (placebo/control). Study III 
was a cluster randomized trial conducted at abortion clinics, youth clinics and maternal health 
clinics (n=28) in Stockholm. The aim was to compare uptake of contraceptive methods, more 
specifically long-acting reversible contraceptive methods, between women receiving 
structured contraceptive counselling (intervention) or standard contraceptive counselling 
(control) (paper III). Satisfaction with the intervention was evaluated from a healthcare 
provider's and receiver's perspective (paper IV) to gather information on feasibility and 
implementability.  
FINDINGS More women opting for a Copper-intrauterine device for emergency 
contraception were using effective contraception at follow-up compared to women opting for 
an emergency contraceptive pill of ulipristal acetate. The IUD group were also less exposed 
to subsequent unprotected sexual intercourse, and most IUD-users would recommend the 
method for emergency contraception to a friend (study I). In an intention-to-treat analysis, the 
reduction of pain with IUD insertion by the use of intrauterine mepivacaine instillation did 
not reach our anticipated difference compared to placebo. In an additional per-protocol 
analysis, the difference in pain between intervention- and control groups was statistically 
significant. Women receiving mepivacaine had a more positive experience of the insertion 
procedure compared to women receiving placebo. The use of intrauterine instillation for pain 
management was well accepted by women (study II). Uptake of long-acting reversible 
contraception was higher among women receiving structured contraceptive counselling 
compared to women receiving standard contraceptive counselling. The intervention also led 
to higher initiation rate of long-acting reversible contraception and fewer cases of subsequent 
pregnancies at 3 months follow-up, compared to control (study III, paper III). The 
intervention received high satisfaction rates from both healthcare providers and patients. 
They found it to be supportive in their contraceptive counselling and choice. Healthcare 
providers estimated the time consumption for using the intervention outside the study to be 
time-neutral compared to standard contraceptive counselling (study III, paper IV).  
CONCLUSION At the 6 months follow up, significantly more women opting for a copper-
intrauterine device for emergency contraception used an effective contraceptive method. The 
results of this study support increased promotion and use of copper-intrauterine devices for 
emergency contraception (study I). Intrauterine instillation of 1% mepivacaine prior to 
intrauterine device insertion modestly reduces pain; however, the effect size may be clinically 
significant with fewer women having a "worse than expected" experience (study II). As a 
stand-alone intervention, structured contraceptive counselling increased uptake of LARCs 
independent on clinic type and might prevent subsequent unplanned pregnancies (study III, 
paper III). The intervention had a high provider and receiver satisfaction. The intervention 
package could be used in several clinical settings to improve quality in contraceptive 
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Unintended pregnancies are a significant health problem resulting in human life loss and 
high costs for societies worldwide. Unintended pregnancies result in many adverse 
outcomes for women and children such as poor health, bad economy and exposure to social 
and psychological vulnerability (1-4). In the US, every dollar invested in helping women 
avoid unintended pregnancies result in a fivefold saving (5). The definition “unintended 
pregnancies” includes all outcomes of pregnancies of which the most common are 
unplanned births, miscarriages from unintended pregnancies and induced abortions (6). In a 
global perspective, women living in developing countries suffer the most with 43% 
unintended pregnancies (7), out of which approximately 40% end in abortion (6). However, 
the proportion of unintended pregnancies in more developed countries is estimated to be 
even higher than in less developed countries, 47% versus 39% (6). (6), and birth is 
considered unintended if it was not wanted at all or if it occurs sooner than desired (8). 
Worldwide, an estimated 99.1 million unintended pregnancies occur every year, out of 
which 56% end in abortion (8). In a global perspective, women living in developing 
countries suffer the most with 43% unintended pregnancies (7), out of which approximately 
40% end in abortion (6). However, the proportion of unintended pregnancies in more 
developed countries is estimated to be even higher than in less developed countries, 47% 
versus 39% (6). The figures differ due to use of different mathematical models to estimate 
proportions of these outcomes, why a process to harmonize the methods to estimate the 
impact of contraceptive use on reproductive health have been initiated (9).  
Unmet need for contraception is part of the explanation behind the high numbers of 
unintended pregnancies. Access to contraception and knowledge about them is mentioned 
by the International Planned Parenthood Federation in their sexual rights declaration (10). 
Unintended pregnancies must be prevented to reach the sustainable development goal 
number 3 “Good health and well-being”, that covers the reduction of maternal mortality 
and global access to family planning (11). Unmet need for contraception is highest in the 
Middle African region at around 26%. The lowest number is found in northern Europe with 
7% unmet need(12). If the worldwide unmet need for contraception was fulfilled, it could 
reduce maternal mortality by nearly one third (13). Uptake of contraceptive methods has an 
enormous impact on reproductive health (14) and has been shown to lower abortion rates 
drastically (15). The unmet need for contraception among Swedish women has increased 
from 8.9% in 2013 (16) to 15.2 % in 2017 (17). This is despite access to contraceptive 
counselling free of charge from a variety of clinical settings such as youth clinics (YCs) and 
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maternal health clinics (MHCs). Also, contraceptive counselling should be offered to all 
women requesting abortion from an abortion clinic (AC) according to national guidelines in 
Sweden. The counselling is given by healthcare providers (HCPs), mainly midwives with 
training in contraceptive counselling and medical eligibility criteria (MEC) for 
contraceptive use. During contraceptive counselling, HCPs inform about available 
contraceptive methods; thus, the counsellor has a prominent role in the election and use of 
contraceptive methods. 
Efficacy and effectiveness of contraception are described in Pearl Index (PI) presenting the 
number of pregnancies among 100 women using the method during a year. The PI for 
typical use (effectiveness), when under the influence of real-life circumstances, including 
both incorrect and inconsistent use, usually is higher than for perfect use (efficacy). 
Effective contraception is commonly defined as having a typical use PI ≤ nine (≥91% 
effective), and highly-effective contraception has a typical use PI ≤1 (≥99% effective)(18). 
All methods for long-acting reversible contraception (LARC) such as intrauterine devices 
(IUDs) and subdermal implants, are highly effective and have the smallest difference 
between typical and perfect use (14). LARCs have also been shown to be highly effective 
in reducing numbers of repeat abortion (19-22).  
Among countries with robust statistics, Sweden has the highest abortion rate (23). Sweden 
also has the highest rate of teenage abortions among Nordic countries (24). One explanation 
could be that a large proportion of Swedish women do not use any contraception at all (17). 
Another possible explanation could be that Swedish HCPs use less effective counselling 
methods in their contraceptive counselling because they are not up to date with the latest 
research and recommendations. Yet, another explanation could be the arrangement of 
contraceptive counselling which is mainly provided during drop-in services at MHCs, 
resulting in quick sessions and information narrowed down to methods already known to 
the user. 
2 BACKGROUND 
2.1 REVIEW—CHOICE OF RELEVANT PUBLICATIONS 
This review is built on the same three topics that represent the foundation of the thesis for 
doctoral degree; IUDs for emergency contraception (EC), pain management during IUD 
insertion and contraceptive counselling. Filters were used only to include articles available 
in English and full text. All publications made before the year 2000 were excluded. Major 
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parts of this review were used in my half-time report. This text is modified, and new 
articles have been added to fit the thesis.  
The relevant outcome of the articles of interest was separate for each topic, including: 
• Provision of different types of EC, pills as well as IUDs, their mechanism of action, 
effectiveness in preventing unintended pregnancies and subsequent use of 
contraception  
• Methods and interventions for pain management during IUD insertion—
pharmacological as well as psychological 
• Contraceptive counselling strategies and how they affect uptake and subsequent use 
of different types of contraception 
Studies with primary or secondary outcomes according to these criteria were included. A 
literature search was done in the Web of Science and Pubmed databases. A search log 
(appendices I, II and III) for each field was used to gain a clear structure of the recently 
published research articles and reviews. A combination of Medical Subject Headings 
(MeSH) in different blocks were used, and relevant articles were identified. Some 
supporting articles were included as appropriate, as well was relevant references from the 
bibliographies of articles already included. 
 
2.2 REVIEW OF RESEARCH FIELD 
2.2.1 IUDs for Emergency Contraception 
Emergency contraception (EC) is used after unprotected sexual intercourse (UPSI) and 
provides a second chance to avoid unintended pregnancy for those without current 
contraceptive use or experiencing contraceptive failure. It is also an important method for 
victims of rape (25) or other kinds of reproductive coercion (26). If used correctly, EC 
prevents pregnancies that otherwise would have occurred (27), and EC is included on the 
Essential Medicines List by The World Health Organization (WHO) (28). EC used to be 
called “the best-kept secret of family planning”, but today bulk of publications on the 
subject are available, and use is widespread. Several medical regimens and methods have 
been used and evaluated for EC (29, 30), and the most common are:  
• Yuzpe regimen: 12 hours separated intake of combined oral contraceptive pills, for 
instance, 100 µg ethinyl oestradiol and levonorgestrel (LNG) 0.5 mg. The first dose 
is taken within 72 hours from UPSI.  
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• LNG 1,5 mg: Single-dose pill taken as soon as possible, but within 72 hours from 
UPSI.  
• Ulipristal acetate (UPA) 30 mg: Single-dose pill taken as soon as possible, but 
within 120 hours from UPSI. 
• Mifepristone (MFP): Taken as low-dose < 25 mg, mid-dose 25-50 mg or high-dose 
> 50 mg within 120 hours from UPSI.  
• Copper-IUD: Inserted within 120 hours from UPSI. 
Effectiveness of EC cannot be calculated in Pearl Index since it is not to be used as an 
ongoing method for contraception. Different methods vary in how effectively they prevent 
pregnancy when used for EC. The least effective method is the Yuzpe regimen, followed by 
the single-dose LNG. UPA and mifepristone are superior to LNG (29, 31), but have not 
been internally compared in terms of effectiveness within the studies screened for this 
review. However, although mifepristone is well known as an agent used for inducing 
abortion, its use for emergency contraception is only registered in five countries, out of 
which China and Russia are the biggest (32). The most effective method of EC is the Cu-
IUD (29).  
Emergency contraceptive pills (ECP) are now available over the counter (OTC) in the 
majority of European countries. In Sweden, both LNG and UPA are found on the open 
shelves in almost all pharmacies. Although ECPs are easy to access, the assumption that 
access would lead to decreased numbers of unwanted pregnancies and abortion has not yet 
been proven (33-36). This can partly be explained by their effectiveness, with LNG 
preventing about 50%- and UPA about two-thirds of pregnancies that would have occurred 
without the use of any other contraception (27). Another explanation is that the mechanism 
of action of the ECPs limits the time window of efficacy. A third explanation is that women 
not initiating use of effective contraception after emergency contraception remains at high 
risk of subsequent pregnancies (31). A fourth and probably most important, explanatory 
factor is an underutilization of ECP. In France for instance, only 11% of women at risk of 
an unintended pregnancy had used any ECP during one year (37), and women do not use 
ECP after every episode of UPSI (36). In addition, women’s awareness of EC as a 
contraceptive method is low. In 2017, only 0.9% of Swedish women were aware of the 
method (17). 
LNG is a progestin that works by delaying or inhibiting ovulation. It is only effective when 
taken in the follicular phase of the menstrual cycle, and before the initiation of increase in 
luteinizing hormone (LH) (38). LNG is evidently most effective if taken within 72 h from 
 
 5 
UPSI (29). UPA, on the other hand, is a progesterone receptor modulator that can be used 
to inhibit or delay ovulation after the onset of the LH rise until the LH peak. Consequently, 
it can be used at a later stage of the menstrual cycle and is effective up to 120 hours from 
UPSI (38, 39). The acceptability for hypothetical new ECPs with a mechanism of action 
consisting of prevention or disruption of the implantation of an early fertilized egg was high 
among women seeking different sexual health care settings in the UK (40). This might be a 
solution to expand the time window for ECP use. A majority of these women were also 
favourable to a “missed-period pill”, to take on the first few days delay of expected 
menstruation (40).  
 In 2011, it was found that high body mass index (BMI >30) of the user could affect the 
effectiveness of the ECP (41). However, subjects within the study population with a high 
BMI was few and so were pregnancies among these women. In contrast, the Cu-IUD is 
independent on the BMI of the treated woman (41). Since UPA is a more effective option 
than LNG, it has been recommended as the first line EC pill. Lately, a risk of incomplete 
delay of ovulation by UPA due to interaction with progestin-containing contraceptives has 
been demonstrated (42). No such interaction is possible for LNG ECP which is a progestin 
in itself. Therefore, recommendations for ECPs depend on the current or planned use of a 
hormonal contraceptive method. If a hormonal contraceptive failure occurs, the 
recommendation is to use an LNG containing ECP (43). 
Low use of effective contraception after EC is a well-known risk for unwanted pregnancy, 
partly since EC-users tend to have repeated UPSIs and, partly because ovulation is delayed 
and the next fertile window might only be postponed. EC users who have repeated 
unprotected sex within the same menstrual cycle have a 2–3 folded risk of pregnancy 
compared to women who abstain from sex (44). Progressive work has been performed to 
increase the use of contraception after EC. One such project was conducted in the UK, 
where women buying their LNG ECP from a pharmacy were provided with a box of 
progestin-only pill (POP) without prescription to enable quick-start. This lead to higher 
subsequent use of contraception compared to standard care that requires women to seek an 
HCP to receive a prescription (45). This is promising, although the follow up was only 6–8 
weeks after EC.  
The Cu-IUD has been used as an EC method for more than 40 years (46). Guidelines 
recommend insertion within five days from UPSI (47, 48) but high effectiveness has been 
seen for insertions up to 10 days (46) and more recently even up to 14 days (49). The Cu-
IUD is highly effective due to a combination of several mechanisms of action, such as 
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spermicidal effect, oocyte destruction, and an endometrial inflammatory reaction (38). It is 
superior to all the other EC methods with a failure rate of 0.09% (50, 51). In addition to the 
EC function, the Cu-IUD provides the user with a LARC for ongoing contraception. The 
risk of experiencing a pregnancy within one year from Cu-IUD insertion for EC is half 
compared to if LNG would have been used. To prevent one pregnancy, the number needed 
to treat is 18 (31). 
Introduction of LNG-IUS for EC would widen the market of available methods. The user 
would also benefit from a LARC that comes with fewer side effects compared to the Cu-
IUD. However, provision of LNG-IUS for EC alone would be unsafe since it takes one 
week after insertion to achieve contraceptive changes in the uterus. These facts are well 
known and reflected in the recommendations about one-week additional use of condoms 
and a pregnancy test conducted after three-four weeks if insertion is later than one week 
from the onset of the last menstruation (52, 53). Thus, the provision of LNG-IUS, together 
with an LNG ECP seems logical. This had been evaluated in a US trial. The trial concluded 
that there was no difference between Cu-IUD or LNG-IUS + LNG ECP for EC users in 
terms of continued use (54). This result contradicts assumptions about higher continued use 
among those opting for LNG-IUS compared to Cu-IUD for EC. The same study reported 
three pregnancies in the LNG-IUS + LNG ECP group compared to no pregnancies in the 
Cu-IUD group, a result that needs to be further evaluated since 43% of study participants 
reported two or more UPSIs in the last two weeks before IUD insertion (55). One of the 
reported pregnancies was not detected at the insertion visit, and one was caused by a missed 
IUD expulsion, ending up in one pregnancy during current IUD use (54). This could have 
happened to any user since PI for the LNG-IUS is 0.2 (14).  
Despite the well-known effectiveness of Cu-IUD for EC, and that they can be safely 
inserted also in nulliparous women (56, 57), few service providers offer or counsel women 
about Cu-IUDs for EC (58-62). This is also reflected in deficient awareness of the Cu-IUD 
for EC among young women who rely on doctors and nurses as their most trusted source of 
information (63). There might be several types of provider bias (further elaborated in the 
discussion part of the thesis) that limit access to- and uptake of Cu-IUDs for EC. One study 
that could be used to exemplify this found that among future healthcare providers in Ghana, 
the knowledge about when to use Cu-IUDs for EC was poor, with some 55% not being able 
to pin-point the time-frame for insertion. Almost 40% considered the use of EC in general 
as morally wrong, and some 55% said EC use promotes promiscuity (64).  
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To decide what method is best suited for EC, a supportive algorithm can be used (65). 
Another useful and supportive tool for the choice of EC, produced by the European 
Consortium for Emergency Contraception (ECEC) is shown in figure 1. 
 
Figure 1. ECEC Wheel
 
Published with permission (granted 2019-10-30) from Cristina Puig Borràs, coordinator of the European Consortium for Emergency 
Contraception.  
 
This thesis includes one study exploring use of effective contraception 6 months after the 
use of either Cu-IUD or ECP for EC (Study I, paper I). 
2.2.2 Pain management during IUD insertion 
One of the most frequently stated reasons for not choosing an IUD is fear of pain during 
insertion (66-70). This has traditionally limited the use of intrauterine contraception, 
especially in nulliparous women. Several publications investigate pain management during 
IUD insertion. However, very few options have proven to be effective (69, 71), and some of 
the effective methods are painful to receive. Although several studies have shown that 
nulliparous women tolerate insertion of intrauterine contraception well (72-74), it would be 
valuable to find a method that is easy for clinics to provide, well accepted by the receiver and 
effective in reducing pain.  
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The most feasible type of pain relief would be some kind of pain medication in tablet form—
easy to access and easy to administer at home prior to the insertion visit. A frequently 
recommended prophylactic prior to IUD insertion is nonsteroidal anti-inflammatory drugs, 
although it has not been proven to improve pain perception (68, 75). No effective reduction in 
pain perception with IUD insertion was achieved by the prophylactic intake of 800mg 
ibuprofen (76). A more recent study found oral 150 mg ketoprofen to be effective when used 
by parous women (77). However, the use of analgesics to ease the pain with IUD insertion 
might not be as important for parous women as for nulliparous women, since their pain scores 
are generally low even with no treatment (76). 
Most IUDs are inserted by an established routine which includes insertion of specula, 
placement of a standard single-tooth tenaculum on the ectocervix (portio) followed by 
sounding the depth of the cavity. Lastly, the IUD is inserted. Pain could be experienced 
during all these procedures. For instance, the use of a uterine sound could be as or even more 
painful than the actual insertion (78). A novel method of using “the bioceptive suction 
cervical retractor” to apply traction on the cervix instead of using the standard one-tooth 
tenaculum during IUD insertion was evaluated in a pilot study. Use of the new retractor was 
associated (not significant) with lower pain scores at placement compared to the single-tooth 
tenaculum, however not significant (79). Another trial suggests that a new simplified routine, 
without performing bimanual palpation or uterine sounding prior to IUD insertion could 
affect pain perception positively since the IUD could still be safely and easily inserted even 
when omitting these procedures (80). 
The pain experienced during insertion is often affected by anxiety and anticipated pain (71, 
81). To examine whether nursing interventions have proven to be efficient in reducing pain 
during IUD insertion or not, a literature review of the results from eight publications was 
conducted (82). This review concludes that different factors, such as no previous vaginal 
delivery and dysmenorrhea, may predispose for a painful IUD insertion. Anxiety is also one 
of these factors (70). Hence, an assessment of each patient’s level of anxiety prior to insertion 
is important, as well as giving comprehensive information and answering questions. 
Distraction through conversations, presence of an assisting person in the room or by holding a 
warm water bottle against the stomach during the insertion could also be effective for 
reducing pain (82). Since there is no best practice advice for these kinds of “verbal 
anaesthesia” (83), they need to be evaluated further.  
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The fear of pain during insertion is most often built on stories about other people’s 
experiences (84). The internet has come to be the most important source for collecting 
information about contraception among adolescents in Sweden (85). Searching the internet 
for peoples experience with IUD insertion results in high numbers of hits, in which many 
reports high levels of pain during insertion and side effects caused by the IUD. This might 
lead to higher expectations of pain. Studies have found that anticipated pain is higher 
compared to experienced pain during insertion (70, 84). This is essential information to be 
given during pre-insertion counselling.  
Many different interventions for application of local anaesthetics have been studied. Topical 
administration of Lidocaine spray to the surface of the outer part of the cervix (portio) before 
tenaculum placement has proven to be efficient in reducing the pain of that specific 
procedure, but it does not decrease pain during insertion (69). A more recent randomized 
controlled study found it to reduce pain, also with sounding and IUD insertion (86). 
However, the findings are clearly less valid since the study was not placebo-controlled. 
Application of 2% lidocaine gel on the portio and intra-cervically does not affect pain during 
insertion (87).  
Intrauterine instillation has also been evaluated. One of those evaluated a new formula of 4% 
lidocaine gel. The gel was applied on the surface of the portio, inside the cervical canal and 
into the uterine cavity prior to IUD insertion. It showed significantly lower maximum pain 
experienced during the first 10 minutes following the insertion compared to placebo (88). 
However, approximately 36% of those receiving lidocaine and 52% of those receiving 
placebo reported the procedure to give “strong” or “very strong” discomfort. In comparison, 
another study evaluating pain during insertion without any pain relief reported moderate or 
severe pain in 33% of the study subjects (73). Thus, the clinical acceptability of this gel could 
be questioned. In another study, investigators infused lidocaine 2% 1.2 ml in both nulliparous 
and parous women using an endometrial aspirator. The difference in pain scores between 
intervention and placebo was 0.7 cm (3.0 vs 3.7, p=0.4) (89). The most recently published 
trial was a double-blinded placebo-controlled four-arm study, in which the study participants 
opting for an IUD were randomized to active oral + active instillation, active oral + inactive 
instillation, inactive oral+active instillation, and inactive oral + inactive instillation prior to 
insertion. Active drugs were oral Naproxen 375 mg (1 hour prior to insertion) and lidocaine 
2% 5 ml naproxen (3 minutes prior to insertion). The instillation was performed with an 
angiocatheter. There were no differences in VAS pain scores between any of the groups and 
mean pain scores varied from 3.62-2.87. Notably, women receiving active oral + active 
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instillation had higher pain scores (mean 3.38) than women receiving just active oral (3.09) or 
active instillation (2.87) (90). 
This thesis includes one study that evaluates a new (at time of study start) non-invasive 
intervention with intrauterine instillation of mepivacaine by a hydrosonography catheter five 
minutes prior to insertion. 
2.2.3 Contraceptive Counselling 
Based on the facts presented in the previous fields, I have chosen to define three main 
outcomes for successful contraceptive counselling: 
• High uptake of highly-effective methods of contraception defined as typical use 
PI<1 
• High continued use of method started 
• High satisfaction with the chosen method  
A ground-breaking study about contraceptive counselling, The Contraceptive CHOICE 
Project, was conducted in the S:t Louis region in the US and included more than 9000 
women. The CHOICE model included a standardized script read to all participants to 
increase their knowledge about different methods. The model also included prototypes of 
different contraceptive methods to be used during counselling sessions. In addition to this, 
HCPs received training in order to increase method-specific knowledge and how to counsel 
according to the CHOICE protocol (91). All included participants received tiered 
contraceptive counselling presenting LARCs as the most effective methods. Whilst 
enrolled, participants were offered their contraception of choice at no cost. Removing the 
cost-barrier and the promotion of LARC led to a LARC uptake of 75% (92). This proves 
that LARC forward counselling is effective to achieve high uptake.  
This type of standardized counselling is referred to as structured contraceptive counselling. 
In a follow-up study, to evaluate the use of the CHOICE model in real-life settings, the 
standardized script to achieve structured contraceptive counselling was used as a single 
intervention for a first group (enhanced care) of women seeking contraceptive counselling. 
A second group also received structured counselling, but this time from providers who had 
undergone contraceptive training and in addition, the costs for contraception was removed 
(complete choice). Women receiving complete choice had a higher uptake of LARCs and a 
lower pregnancy rate at 12 months follow up (93). The term structured contraceptive 
counselling has also been used in other trials. Structured counselling often includes audio-
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visual information, presenting evidence-based information, which has been proven effective 
in increasing use of contraception among sexually active men (94) and continued use of 
contraceptive injections and pills among women (95). However, structured contraceptive 
counselling in settings providing all contraceptive methods free of charge does not always 
result in higher uptake of LARCs, which was the outcome of a study by Langston et al. 
(96). This used another type of structured counselling called DMT, a double-sided flipchart 
in a post-abortion setting. This chart includes one side for the patient and one side for the 
provider, to aid for contraceptive choice and contraceptive counselling (97). In a cluster 
randomized trial evaluating structured contraceptive counselling no increased use of 
LARCs could be seen among patients included from abortion clinics (98). It seems like this 
patient category needs an even more refined method for structured contraceptive 
counselling than used in those studies.  
 To remain effective, contraception has to be continued over time. One factor determining 
continuation is user satisfaction. IUDs, in particular, have a higher continuation and 
satisfaction rate than any other contraceptive method. The 12 months continuation rate for 
the Cu-IUD is just slightly lower than for LNG-IUS, 84% versus 88% (99). The Cu-IUD 
increases menstrual bleeding and menstrual cramping (100), and these side effects 
constitute the most common reasons for requesting IUD removal (101, 102). However, 
these side effects have been reported to decrease with time, as do method satisfaction 
improve (103). In a study evaluating satisfaction among nulliparous women, the statement 
“very happy or “happy” with their IUD was presented by 83% of the 109 women who 
participated in the follow-up. No statistical significance was found between LNG-IUS and 
Cu-IUD users (104). As this study was published, it contributed to fill a knowledge gap 
about continued use solely among nulliparous women, since the previous publications from 
CHOICE did not separate nulliparous from parous women in their findings (99). In a later 
article, the data from CHOICE was stratified by age groups, and the results were presented 
by the continuation rate for different contraceptives in each age-group. Continued use of 
LARCs was higher in comparison to non-LARCs in all age groups, and above 75% for all 
LARCs compared to the highest figure of 51% for non-LARCs (105).  
The impact of LARC forward counselling in Sweden is unknown, and study findings report 
lower method awareness of LARCs compared to SARCs among both contraceptive users 
and non-users (16). In the year 2013, among women aged 16–29, more than 50% were 
currently using SARCs and less than 20% were LARC users (16). This is also seen in the 
statistics for medical prescriptions in Sweden. In 2016, 1 324 518 prescriptions of SARCs 
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were collected, compared to 113 986 prescriptions of LARCs (106). IUDs are the most 
cost-effective methods (107) and are also the most eco-friendly in terms of environmental 
impact (108). These arguments, together with the fact that several studies have shown that 
LARC promotion leads to a reduction of unintended pregnancies and repeat abortions (22, 
109)  should appeal to Swedish stakeholders and contraceptive users.  
The third study in this thesis evaluates the effects of an intervention of structured 
contraceptive counselling on LARC uptake. The intervention emphasizes the effectiveness 








Emergency contraception is an important opportunity to give contraceptive counselling. Few 
healthcare providers actively counsel women about Cu-IUDs for EC, despite its superior 
effectiveness compared to ECPs. Knowledge among women and providers are low 
concerning the use of Cu-IUD for EC. By lowering the thresholds to insertion of Cu-IUDs, 
we can increase LARC use and by that decrease number of unintended pregnancies.  
The barrier of pain toward IUD insertion is well known. Some effective methods exist; 
however, the urge for a highly effective method that is acceptable to patients and is easy to 
access for providers is large.  
Contraceptive counselling is given to provide women with comprehensive information about 
available contraceptive methods. Different kinds of interventions introducing structured 
contraceptive counselling have been evaluated, most of them resulting in higher uptake of 
LARCs and lower pregnancy rates. However, within abortion clinics, interventions have 
failed to affect LARC uptake. The effects of structured contraceptive counselling in a high-
income setting with existing contraceptive subsidies need to be evaluated, as well as 
satisfaction with the interventions used from an HCP’s and receiver’s perspective.  
Increasing the use of LARCs is to date without a doubt the most effective way of reducing 
unintended pregnancies and hence decreasing the numbers of abortions, much likely also in a 
Swedish setting.  
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4 AIMS AND OBJECTIVES 
4.1 OVERARCHING AIM 
This thesis includes original research within three subfields that all represent opportunities 
for provision of effective contraception. The overall aim is to find pathways to increase 





• To compare use of an effective method of contraception 6 months following 
insertion of a copper intrauterine device or intake of ulipristal acetate for emergency 
contraception. 
(Paper I) 
• To evaluate whether intrauterine mepivacaine instillation before intrauterine device 
insertion decreases pain compared to placebo. 
(Paper II) 
• To evaluate the effect of structured contraceptive counselling on LARC uptake and 
pregnancy rates in abortion clinics, maternal health clinics and youth clinics. 
(Paper III) 
• To evaluate user satisfaction of healthcare providers and participants with an 
intervention used in a cluster randomized trial and to characterize which providers 






5 MATERIAL AND METHODS 
 
5.1 TABULATED OVERVIEW OF STUDIES 
 
Table 1. Overview of study design, participants and methods 
 Research question Design and 
participants 





Is insertion of Cu-IUDs 
for emergency 
contraception an effective 
way to increase 









Primary outcome use of 
effective contraception 
measured at 6 months 
follow up. Secondary 
outcomes measured at 3 
and 6 months follow up.  
Descriptive statistics and 
multivariable logistic 













opting for an IUD 
(n=86). 
Primary outcome VAS 
pain scores at insertion 
procedure steps 
measured immediately 
after each step. 
Secondary outcomes 
measured at 7–10 days, 
3 months, and 6 months 
follow-up. 
Descriptive statistics and two 
group comparisons. Intention 






with emphasis on method 
specific effectivity an 







Patients ≥18 years, 
sexually active 




LARC measured at first 
visit. Secondary 
outcomes measured at 3 
months follow-up.  
Descriptive statistics of 
clinics and participants. 
Logistic mixed models with 




How do healthcare 
providers and patients 
experience use of the 
intervention for structured 
contraceptive counselling 
and do they find it to be 
supportive in their 
counselling and 









User satisfaction with 
intervention measured 
immediately after first 
visit (participants) and 
after completed 
enrolment of study 
participants (healthcare 
providers).  
Descriptive statistics and two 




5.2 RESEARCH SETTING 
In Sweden, contraceptive counselling can be accessed in a variety of settings. Midwives 
provide most counselling and prescriptions in YCs and in MHCs. Gynaecologists also issue 
prescriptions, but that is more common in cases of discovered contraindications or health 
issues that need to be considered by a physician. All women requesting an abortion are by 
routine receiving contraceptive counselling.  
A YC is a clinic for adolescents and young people between 12 and 25 years of age. They 
are staffed with midwives, social counsellors and are supported by consultant 
gynaecologists and paediatricians. The youths do not have to suffer from a medical 
condition or mental health issues to seek care from a YC. The YCs are open on a year-
round basis with no exception for school holidays. Examples of services provided by the 
YCs are sexual- and reproductive health counselling including contraception, EC, 
pregnancy testing, STI testing and other health issues such as stress, anxiety, depression 
and eating disorders. Most contraceptive counselling is provided during scheduled 
appointments, but drop-in services are also available. The YCs are operating on behalf of 
the municipality or the region (former county council).  
MHCs are staffed with midwives with the assignment to monitor pregnancy and taking care 
of pregnant women’s health. The assignment also includes screening for cervical cancer 
and contraceptive counselling. The services include scheduled appointments for 
contraceptive counselling but most clinics, at least in Stockholm region, meet most of their 
patients during drop-in services. These services are, unfortunately, often limited by time 
and midwives are meeting with vast numbers of patients during each drop-in session. The 
MHCs in Stockholm is operating on behalf of the region.  
Midwives at Swedish YCs and MHCs play an essential role in providing effective 
contraception and are most often skilled inserters of IUDs and contraceptive implants. 
In Sweden, abortion is conducted upon the request of the woman up to gestational week 18. 
Between week 18-22 a permission has to be granted from the National Board of Health and 
Welfare (Socialstyrelsen). The ACs are staffed with midwives, medical doctors and nurses. 
Some clinics are run independently by midwives with special training. Abortions are 
generally made early in pregnancy, with 57% performed before week 7 and 84% before 
week 9. In 2018, 93% of abortions were medical. Contraceptive counselling is included in 
the abortion care, with midwives providing most of the counselling.  
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Study I and II were conducted at a sexual health clinic in Stockholm, the RFSU Clinic run 
by the Swedish Association for Sexuality Education on behalf of the region. Annually the 
clinics meet with 12 000 patients during 19 000 healthcare meetings. The most common 
reason for visiting the clinic is STI testing, but a large number of patients also seek the 
clinic to receive contraceptive counselling. The clinic is open for patients with a lower age 
limit of 18. No underaged patients are rejected care, but they are advised to seek care from 
a YC if in need of future reproductive health services. The clinic is located in the city centre 
of Stockholm, and visitors come from all over the country, but most commonly they are 
residents living in the Stockholm region. This results in a variation of visitors with regard to 
migrant and educational status. The clinic offers both drop-in services and scheduled 
appointments.  
Study II was also conducted at a YC in Upplands Väsby. This YC is located in the centre 
of Upplands Väsby incorporated in a shopping mall. The location is suitable for youths 
since there is no apparent reason for visiting a shopping mall. Annually, midwives within 
the YC see approximately 1200-1500 patients. This clinic serves a mixed group of patient 
with regard to migrant status. Most contraceptive counselling is provided during scheduled 
appointments.  
Study III was conducted at ACs, YCs and MHCs in the Stockholm region.  
Recruitment processes are explained in the following section of the thesis.  
5.3 PROSPECTIVE OBSERVATIONAL COHORT STUDY. STUDY I, PAPER I 
5.3.1 Study design and hypothesis 
Study I was a prospective observational cohort study. The hypothesis was that patients 
opting for a Cu-IUD would use effective contraception at 6 months to a higher extent 
compared to patients opting for UPA (primary outcome). In addition, we hypothesized that 
participants in the Cu-IUD group would have had less unprotected sexual intercourses and 







5.3.2 Population, groups and outcomes 
 
Table 2. Summary of study population, groups and outcomes 
Population Patients presenting with need of emergency contraception 
Group 1 Cu-IUD for emergency contraception  
Group 2 UPA for emergency contraception 
Primary outcome  Use of an effective contraceptive method at 6 months follow up 
Secondary outcomes Adverse events, use of an effective contraceptive method at 3 months 
follow up, method acceptability, reason for choosing either Cu-IUD or 
UPA for EC, subsequent unprotected sexual intercourse, pregnancies 
5.3.3 Details on primary and secondary outcomes 
The primary outcome use of effective contraception was selected a priori and was defined 
as methods having a typical use PI of less than nine. We included IUDs (hormone-releasing 
and copper), implant, COC, vaginal ring, patch, POP and injections in our definition of 
effective contraception according to the most used report from contraceptive failure in the 
United States (14). Use of effective contraception at 6 months follow-up was set as the 
primary outcome since we hypothesized that the low effectiveness of ECP was due to the 
fact that few women initiate effective contraception after the use of ECP. In addition, we 
hypothesized that most IUD users would remain with their device for at least 3 months to 
give themselves a chance to evaluate the method fully. Use at 3 months as a secondary 
outcome was an important endpoint since the loss to follow-up usually increases the longer 
the time to follow-up.   
Adverse events during IUD insertions and use of ECPs are rare. Vasovagal reactions or 
syncope might happen during IUD insertion, as well as IUD dislocation, uterine perforation 
and insertion failure (110, 111). We measured vasovagal reactions and/or syncope and 
insertion failures at first visit. During follow-up, other complications related to the IUD 
were reported, such as heavy bleeding and excessive pain. Any adverse events were 
recorded in the patient’s medical record and managed by the provider according to clinical 
practice. Any other side effects related to the method used for EC, such as tender breasts, 
nausea, irregular bleeding and headache, were also reported.  
We measured the acceptability of Cu-IUD for EC at first visit by asking two questions; 
would you choose Cu-IUD if you were to use EC again and would you recommend Cu-IUD 
for EC to a friend? Another measure of acceptability was insertion experience described as 
easier than expected, as expected or worse than expected. At follow-up participants opting 
for Cu-IUDs were asked whether they would opt for another IUD taking the experience of 
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the first period of use into account, and if they would recommend and already had 
recommended IUD insertion to a friend. Continued use of Cu-IUD and reasons for IUD 
removals were recorded at the follow-up to get a broader idea of user satisfaction with the 
chosen method and why patients chose not to remain with their IUD.  
Reasons for choosing either Cu-IUD or UPA for EC was recorded at the first visit, for 
instance, “fear of pain with IUD insertion”, and grouped after similarity to calculate 
proportions. Subsequent unprotected sexual intercourse and Pregnancies were self-reported 
and measured at both 3 and 6 months follow-up.  
5.3.4 Eligibility criteria 
All patients were screened for the need of EC by using standardized questions asked to all 
clinic visitors; do you use any contraception, and when did you last have unprotected sex? All 
patients who reported unprotected sexual intercourse within the last 5 days were assessed for 
eligibility. Patients ≥18 years and with an ability to use both UPA and the Cu-IUD were 
included. We excluded patients with a known uterine anomaly, cervical stenosis, previous 
conization, signs of ongoing genital infection, and known bleeding disorder.   
5.3.5 Enrolment and obtaining informed consent 
Eligible patients received verbal and written study information, including study purpose and 
could ask questions prior to inclusion. Women who chose not to participate received method 
according to choice as per clinical practice. Study information was available in Swedish. All 
patients opting for a Cu-IUD received a gynaecological exam to screen for ongoing genital 
infection (e.g. abnormal vaginal discharge or pronounced inflammatory reaction). If the 
provider found an ongoing infection, the patient would have been excluded and replaced with 
another study participant. However, no such cases were reported. All patients accepting 
participation signed informed consent. 
All participants received structured counselling about EC with emphasis on the effectiveness 
of Cu-IUD over UPA. Group allocation was according to method preference. 
Patients opting for UPA were given a single dose 30mg oral UPA (ellaOneÒ) free of charge, 
to be taken immediately. They were informed about known side effects and that another pill 
was recommended if vomiting occurred within three hours from intake. The importance of 
initiating an effective method of contraception after the back-up period was highlighted (42), 




Prior to insertion, patients opting for a Cu-IUD received information about insertion 
procedure, known risks and side effects and about the importance to seek care if experiencing 
heavy bleeding, excessive pain and/or signs of infection. Patients were also informed to keep 
their Cu-IUD at least until their next menstrual period. They were offered oral pain 
medication (1g paracetamol and 400 mg ibuprofen) according to clinical practice and had the 
device (Nova-T 380Ò) inserted at the first visit according to protocol. Patients were free to 
leave the facility once they felt ready. 
5.3.6 Clinical assessments  
First visit 
• Reproductive and gynecological history icluding last menstrual period, ongoing 
bleeding, gravidity, parity, and previous medical and/or surgical abortions  
• Pregnancy test  
• Standard protocol for IUD insertions including bimanual palpation, gynecological 
exam and measurement of uterine size (no ultrsound).  
• Vasovagal reactions or syncope 
Follow-up 
• Complications and side effects of chosen method 
In accordance with the study site protocol for EC, all participants were offered a follow-up 
visit after three weeks to rule out pregnancy and to allow for participants to ask questions and 
receive further contraceptive counselling if needed. No data collection for the study outcomes 
were collected at this visit, nor were any IUD removals or prescription of other contraceptive 
methods recorded. 
5.3.7 Follow up and measurement of outcomes 
Follow up data were collected through telephone interviews. The primary outcome was 
measured at 6 months follow-up. Secondary outcomes were measured at the first visit and 3 
and 6 months follow-up. Follow-up data were mainly collected by a research team member 
who had not been involved in any previous study-related activities in a strive to reduce social-
desirability bias caused by the patient-provider relationship (112). To collect data within the 
given time frame for follow-up and to decrease loss to follow-up, some participants were 
contacted by one of the investigator midwives who had provided the EC. 
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5.3.8 Sample size 
We hypothesized a difference in the use of effective contraception 6 months after use of 
emergency contraception, with higher proportions among participants opting for a Cu-IUD 
than participants opting for UPA. We expected the use to be 90% in the Cu-IUD group and 
30% in the UPA group. The sample size was calculated to show the 30% anticipated 
difference between groups with a power of 80% and an alpha of 0.05, resulting in 32 
participants in each study arm. To allow for 20% loss to follow up, we aimed at recruiting a 
total of 39–40 in each group. 
5.3.9 Data management 
All participants received a study-id. This number was stored together with the participant’s 
full name, personal identity number (i.e. social security number) on a specific separated list 
that served as a code key. All data from first visit and follow-ups were collected on paper 
CRFs and manually transferred into a computer-based spreadsheet prior to analyses. 
5.3.10 Analyses 
Participants in both groups received their preferred method for EC at the first visit. We did 
not collect any data on repeated use of EC due to vomiting within three hours, and no such 
cases were reported at follow-up. Hence analysis was made according to intention-to-treat 
(ITT). A two-sided p-value of <0.05 was considered statistically significant.  
Descriptive statistics with chi-square tests and Fisher’s exact tests were used to compare 
baseline characteristics and categorical outcomes between groups. Mann-Whitney U-tests 
were used for comparison of non-normally distributed variables such as age and parity. 
Variables that might affect primary and secondary outcomes were analyzed in a binary 
logistic regression. We included and dichotomized age (≥25 or <25 years), gravidity (yes/no), 
parity (yes/no) and current use of contraception (yes/no). All data analyses were performed in 
SPSS version 23. 
5.4 DOUBLE-BLIND, RANDOMIZED, CONTROLLED TRIAL 
5.4.1 Study design and hypothesis 
Study II was a double-blind, randomized, controlled trial. We hypothesized that intrauterine 
mepivacaine instillation would numb the uterine and cervical lining and reduce pain with 
IUD insertion. We also hypothesized that mepivacaine would provide a more effective pain 
relief than saline solution (NaCl). 
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5.4.2 Population, intervention, control and outcomes 
Table 3. Summary of study population, intervention, control and outcomes 
Population Nulliparous patients opting for an intrauterine device 
Intervention Intrauterine instillation of mepivacaine 5 minutes prior to insertion 
Control/Placebo Intrauterine instillation of NaCl 5 minutes prior to insertion 
Primary outcome  Difference in VAS score with IUD insertion between intervention and 
placebo 
Secondary outcomes Adverse events, VAS with intrauterine instillation, all insertion procedure 
steps and VAS when leaving the clinic, method acceptability, continued use 
of IUD 
 
5.4.3 Details on primary and secondary outcomes 
Primary outcome VAS score with IUD-insertion was measured using a paper-printed 10-cm 
visual analogue scale, marked with no pain at the 0-cm anchor point and worst pain 
imaginable at the 10-cm anchor point. The same procedure was used for measuring the 
VAS scores of the secondary outcomes. Patients generally left the clinic within 10 minutes 
after insertion, but no exact time-frame from insertion to this VAS measurement was 
calculated.  
Adverse events and any other complications and/or side effects were measured and recorded 
in the same manner as presented in the previous study. One important difference was that 
patients with any such experience were encouraged to seek the healthcare facility that 
performed the IUD insertion since the follow up was also blinded to the interviewer. 
Method acceptability was measured with four questions on intrauterine instillation and IUD 
insertion: I would opt for another IUD if I knew it would be like this (yes/no); I would 
recommend others to use IUD after this IUD insertion (yes/no); I would recommend this 
method for pain relief to others (yes/no); In comparison to my expectations, this IUD 
insertion was (easier than expected/as expected/worse than expected).  
To get a broader idea of user satisfaction, Continued use of Cu-IUD, as well as reasons for 
IUD removals, were measured at follow-up. In addition, patients were asked if they were 
pleased with their IUD (yes/no/somewhat pleased). 
5.4.4 Eligibility criteria 
All patients opting for an IUD for pregnancy prevention were screened for eligibility. Eligible 
patients were 18 years or older and nulliparous. Exclusion criteria were previous conization, 
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known cervical stenosis, signs of ongoing genital infection, known uterine abnormality, 
bleeding disorder or any local anesthetic contraindication. 
5.4.5 Randomization and masking 
A study coordinator not involved in any other participant-related work prepared opaque, 
sealed and numbered envelopes. A computer-generated randomization list with random 
permuted blocks of 6 to 10 from www.randomization.com was used. Eligible patients were 
randomly assigned to intervention (mepivacaine 1% 10 ml) or control group (NaCl 09% 10 
ml) in a 1:1 allocation ratio by consecutive opening of envelopes containing the allocation 
code unique to each study site. The randomization and preparation of study drug were 
performed without the presence of the study investigator or the participant, hence double-
blinded. Blinded research personnel outside the clinics performed the follow-up. 
5.4.6 Enrolment and obtaining informed consent 
Eligible patients received verbal and written study information, including study purpose, IUD 
type according to preference (not free of charge) and alternatives to participation (no 
intrauterine instillation). All patients could ask questions prior to inclusion. Study information 
was available in Swedish. All patients received a gynecological exam to screen for ongoing 
genital infection (e.g. abnormal vaginal discharge or pronounced inflammatory reaction). If 
the provider found an ongoing infection, the patient would have been excluded and replaced 
with another study participant. However, no such cases were reported. All patients accepting 
participation signed informed consent. 
5.4.7 Details on intervention and control 
Participants were informed about the study procedure, known risks and side effects and about 
the importance to seek care if experiencing heavy bleeding, excessive pain and/or signs of 
infection prior to intrauterine instillation and IUD insertion. Participants received an 
intrauterine instillation of the assigned study treatment (mepivacaine or NaCl) with a sterile 
hydrosonography catheter (figure 1). This catheter is thin (1.6 mm) and flexible without a 
balloon tip. After instillation, participants remained in lithotomy position for 5 min to allow 
for the fluid to act on the uterine and cervical lining. Then the IUD insertion was performed 
according to a standardized protocol to remove any disparities in insertion technique.   




Figure 1. Hydrosonography catheter used for intrauterine instillation 
 
5.4.8 Clinical assessments  
First visit 
• Reproductive history including gravidity, parity, and previous medical and/or surgical 
abortions 
• Gynecological history including last menstrual period, ongoing bleeding, numbers of 
days with “fresh blood” during normal period, pain score on a 10 point VAS for 
normal period cramping, intake of pain madications during normal period 
• Pregnancy test  
• Standard protocol for IUD-insertions including bimanual palpation, insertion of 
sprecula, gynecological exam, tenaculum placement and measurement of uterine size 
(no ultrsound) followed by IUD placement  





• Current pain related to IUD or period on a 10 point numerical scale.  
• Ongoing bleeding  
• Complications and side effects of chosen method 
5.4.9 Follow up and measurement of outcomes 
Follow up data were collected through telephone interviews. Primary outcome was measured 
at first visit. Follow-ups to collect secondary outcomes were performed at 7-10 days, 3 and 6 
months after the insertion. Follow-up data werw collected by a research team member who 
had not been involved in any previous study related activities and the participant’s study 
allocation was blinded.  
5.4.10 Sample size 
In a previous study assessing IUD insertion pain after pretreatment with misoprostol, the 
mean pain score in the control group was 6.5±1.8 on a 10-cm VAS (113). We hypothesized 
a 20% decrease in VAS pain score in our intervention group, equivalent to an absolute 
decrease of 1.3 cm, consistent with previous studies on clinically relevant reduction of VAS 
for acute pain (114, 115). To demonstrate this difference with a power of 90% at an alpha 
of 0.05, each study arm needed 38 participants. To account for an expected loss to follow-
up of 10% to 15%, we aimed to enrol 86 participants. 
5.4.11 Data management 
All participants received a study-id. This number was stored together with the participant’s 
full name, personal identity number (i.e. social security number) on a specific separated list 
that served as a code key. All data from first visit and follow-ups were collected on paper 
CRFs, and manually transferred into a computer based spreadsheet prior to analyses. 
5.4.12 Analyses 
Participants’ study allocation remained blinded until data analysis. Type of IUD was 
according to participants’ preference, and IUD types inserted in the study were two 
levonorgestrel (LNG) intrauterine system (IUS) products containing 52 mg (Mirena®)or 
13.5 mg (Jaydess®) and one copper IUD (Nova-T 380®). 
To perform an adequate instillation, the hydrosonography catheter had to be inserted at least 4 
cm to reach the internal cervical os. One of the study investigators excluded one participant in 
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each study arm from further participation (no data collection) since this depth was not 
reached (both received their IUDs). After consulting the principle investigator, this 
management was changed, and all other instillations were performed as intended, and 
participants were included in an ITT analysis. An additional per-protocol (PP) analysis for the 
primary outcome was performed in which three inadvertently enrolled underaged women 
were excluded. A two-sided p-value of <0.05 was considered statistically significant. 
Inferential statistics with independent sample t-test was used to compare baseline 
characteristics between groups. Mann-Whitney U-tests were used for comparison of non-
normally distributed variables such as age and period cramping as well as VAS scores. 
Variables that might affect primary outcomes were analyzed in a multivariable linear 
regression that showed no differences and thus omitted from the article (paper II). Chi-square 
tests and Fisher’s exact tests were used as appropriate for categorical variables. All data 
analyses were performed in SPSS version 24.0. 
5.5 CLUSTER RANDOMIZED TRIAL (PAPER III & IV) 
5.5.1 Study design and hypotheses 
Study III was a cluster randomized trial conducted in abortion clinics (AC), youth clinics 
(YC) and maternal health clinics (MHC) in the Stockholm region. We hypothesized that 
more participants receiving contraceptive counselling according to a specific structure 
(intervention) would choose/receive prescriptions of LARCs compared to participants 
receiving standard contraceptive counselling (control). We also hypothesized that more 
participants in the intervention arm would have initiated LARC use and would have a lower 
pregnancy rate at follow-up than participants in the control arm (paper III). To evaluate user 
satisfaction with the intervention, participants from intervention clinics were asked specific 
questions and healthcare providers from intervention clinics were invited to complete a 




5.5.2 Population, intervention, control and outcomes 
Table 4. Summary of study population, intervention, control and outcomes 
Population Patients receiving contraceptive counselling (paper III & IV) 
Healthcare providers giving structured contraceptive counselling (paper IV) 
Intervention Structured contraceptive counselling comprising:  
- Educational video  
- 4 key-questions  
- Effectiveness chart of avaliable contraeceptive methods  
- Box of contreceptive models  
Control Standard contraceptive counselling 
Primary outcome  LARC uptake (paper III).  
Scondary outcomes LARC initiation, pregnancies (paper III).  
User satisfaction with intervention (paper IV). 
5.5.3 Details on primary and secondary outcomes 
The primary outcome was the proportion of participants with uptake of LARCs. Uptake 
included choice and prescriptions where applicable. The outcome selection was made a 
priori to measure the intervention effect on the patients’ intention to use LARCs at the first 
visit. This information was collected from questionnaires completed by the healthcare 
provider.  
LARC initiation was defined as having had an IUD or contraceptive implant inserted within 
the follow-up period. Data were self-reported, and no imputation was used to account for 
missing data due to loss to follow-up or withdrawal.  
Pregnancy data (yes/no) and how the participant chose to deal with the pregnancy 
(preparing to give birth/planning an abortion/had an abortion/had a miscarriage/any other 
outcome/undecided) was also self-reported. However, for participants with missing data 
due to loss to follow-up, electronic records were scrutinized for any visits to obstetrics and 
gynaecology units or maternal health clinics in order to rule out current pregnancy or 
abortion. This outcome was selected to assess if the intervention affected contraceptive 
uptake and resulted in fewer pregnancies. User satisfaction with the intervention was 
collected from participants at the first visit.  
Healthcare providers received and completed a questionnaire after study enrolment had 
stopped. Participants and providers evaluated the educational video, the effectiveness chart 
and the box of contraceptive models. Also, providers evaluated the use of key-questions 
and rated their satisfaction with the intervention as a whole. Ratings of the different 
intervention parts was: very good, good, no opinion, poor, very poor. Participants and 
providers were asked if they found the intervention parts to be supporting their 
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contraceptive choice/counselling (yes/no). Providers also assessed time consumption to 
perform their counselling according to the intervention. This was measured on a 30-minutes 
VAS marked with -15 minutes at the left anchor point and +15 minutes at the right anchor 
point. Providers were also asked if they considered the intervention to affect the patients’ 
contraceptive choice and whether they would like to use the intervention in their routine 
counselling after completion of the study.  
5.5.4 Eligibility criteria 
There were no specific inclusion or exclusion criteria for clinics, such as number of visitors 
per year, migrants within the catchment area or baseline prescription of LARC. All abortion 
clinics, youth clinics and maternal health clinics providing contraceptive counselling within 
the Stockholm region were eligible. The only exclusion criteria was ongoing competing study 
participation. 
Eligible patients were ≥18 years, sexually active or planning to be sexually active within 6 
months and had pregnancy prevention as primary purpose of their contraception. Patients 
were excluded if they had undergone sterilization or had a sterilized partner.  
5.5.5 Randomization and masking 
Randomization was stratified by clinic type. For youth- and maternal health clinics 
randomization was also stratified by proportion of migrants within their catchment area. 
Randomisation was performed by an independent statistician using the statistical software R 
(version 3.4.0). Clinics were allocated to intervention or control at a ratio of 1:1 within each 
clinic type. Randomization masking of clinic allocation was not possible since healthcare 
providers at intervention clinics received study specific training.  
5.5.6 Training of healthcare providers 
Before study initiation, in addition to a start-up meeting at all study sites, HCPs at 
intervention clinics were invited to participate in a 3-hour training session. Participating 
HCPs received updates from previous research within the field of contraception and 
contraceptive counselling with emphasis on method-specific effectiveness and effectiveness. 
HCPs were also introduced to the study procedure, the four different parts of the intervention, 
and how they were meant to be used in the study-specific structured contraceptive 
counselling. The research team also offered training in LARC insertion skills. However, there 




5.5.7 Enrolment and obtaining informed consent  
An open invitation was sent to abortion clinics, youth clinics and maternal health clinics in 
the Stockholm region. Clinics were informed about the study design and that an intervention 
of structured contraceptive counselling was to be evaluated with regards to participants’ 
uptake of contraceptive methods (paper III) as well as user satisfaction from both an HCP’s 
and patient’s perspective (paper IV). Clinics were offered a meeting with a member of the 
research team to receive more details about the trial and to be able to assess what 
participation would mean to the healthcare providers who would include patients in the study. 
No further details of the intervention or study outcomes were discussed in order to minimize 
spillover to clinics which would eventually be randomized to control, except the fact that 
clinics randomized to intervention would receive study-specific training. A total of 33 clinics 
accepted participation. 
Patients receiving contraceptive counselling from participating clinics were informed about 
the study. They were either addressed by a clinic assistant, the healthcare provider or a 
member of the research team. Prior to receiving full study information, patients were 
screened for eligibility. Written information was available in Swedish and English. In case of 
insufficient language skills, study information was translated by a professional interpreter, 
and these participants were informed to complete the follow-up questionnaires together with 
someone who could translate the questions. The information included study design, the 
purpose of the study presented as intervention effect on uptake and continued use of 
contractive methods, the period for follow-up and clinic group allocation (intervention or 
control). Furthermore, they were informed about alternatives to participation (contraceptive 
counselling according to clinical routine). All patients accepting participation signed 
informed consent.  
HCPs from intervention clinics received an email with an invitation to evaluate the 
intervention after enrolment of study participants had stopped (paper IV). An electronic 
survey was linked to the email, and the providers were informed that completing the survey 
meant that they accepted study participation and gave their consent for the research team to 
collect and store information of them as study subjects. 
5.5.8 Details on intervention and control 
The intervention consisted of four different parts: 
1. A seven minute long educational video with members of the research team presenting 
available contraceptive methods with emphasis on effectiveness, mechanism of 
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action, administration and added health benefits of the different contraceptive 
methods. The video was to be seen by the participant prior to meeting with their HCP. 
2. 4 key-questions to be asked by the healthcare provider. Questions were formulated to 
make the participant reflect on how to deal with a pregnancy if it was to occur at that 
moment, for how long contraception was needed and to describe menstrual period 
cramping and bleeding. 
3. A modified tiered effectiveness chart (116) of avaliable contraceptive methods. Our 
effectiveness chart presented typical use failure rate of available methods in percent 
(%) on the left side and in modified Pearl Index with numbers of pregnanies among 
10 000 users on the right side (figure 2). 
4. A box of contraceptive models. The prototypes were shown to participants for them to 
see actual method size and to easier explain administration and insertion of methods 
(figure 3).   
Participants at intervention clinics received the study-specific structured contraceptive 
counselling. Participants at control clinics received standard contraceptive counselling. 
Standard contraceptive counselling follows no specific structure. All contraceptive 
counselling was given by midwives or medical doctors. These HCP categories are as such 































































5.5.9 Clinical assessments 
First visit 
• Intended method for contraceptive use (prior to counselling) 
• Reproductive and contracpetive history including gravidity, parity, previous medical 
and/or surgical abortions, previous and current use of contraceptive methods 
• Contraindications for contracetive use 
Follow-up 
• Contraceptive initiation and reasons for non-initation or termination 
• Change in contraceptive use and underlying reason 
• Complications and side effects of chosen method 
• Unprotected sexual intercourse 
• Pregnancies and how these were handled 
5.5.10 Follow-up and measurement of outcomes 
Follow-up data were collected through electronic questionnaires sent by email. Participants 
who did not finish their surveys were contacted by SMS or telephone. The primary outcome 
was assessed at the first visit. Follow-ups to collect data on secondary outcomes were 
performed at 3 months and are currently planned for 6 and 12 months with results finalized in 
May 2020. Most telephone interviews to collect follow-up data were performed by research 
team members who had not been involved in any previous participant related study activities. 
None of the follow-ups was performed by HCPs who provided the counselling. To minimize 
numbers of participants lost to follow up, a team member who administered almost all 
enrolment at maternal health clinics also conducted telephone interviews. 
5.5.11 Sample size 
Because of the cluster design, an intraclass correlation (ICC) factor affects the sample size, 
making the number of participants needed larger compared to non-cluster trials. The sample 
size was calculated to show a difference in proportions of participants choosing LARCs in a 
two-group comparison between intervention and control groups. An assumed ICC of 0.05 
was used, equivalent to the ICC observed in a previous study (98). We expected the mean age 
of patients seeking contraceptive counselling to be approximately 25 years. At the time of 
study start, current use of LARCs among Swedish women aged 18–29 was 15% (16). We 
expected that 30% of participants in the intervention arm would choose LARCs. To show the 
anticipated 15% difference in LARC choice with a 90% power at an α=0·05 the aim was to 
include 24 clinics, contributing with an average of 50 participants. This would result in 600 
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participants in each group, yielding a total sample size of 1200. To allow for a lower mean of 
30 participants per clinic, 28 clinics were included. The sample size calculations were 
performed by using the package CRTSize in R version 3.4.0. No power calculation was 
performed for secondary outcomes. 
5.5.12 Data management 
All HCPs received a provider-id. This number was stored together with the name of the 
provider on a separated list and served as a code key. Providers recorded their id in the 
electronic questionnaires that was administered for each study participant that received 
contraceptive counselling (paper III). The list was used to collect email addresses to which 
the invitation to evaluate the intervention was sent. Data was collected in an electronic survey 
and exported to a computer-based spreadsheet prior to analysis (paper IV). 
All participants received a study-id. This number was stored together with the participant’s 
full name, personal identity number (i.e. social security number) and email address (used for 
follow up) on a specific separated list that served as a code key. All data from the first visit 
and follow-up were collected in electronic questionnaires and was exported into a computer-
based spreadsheet. Copies of first visit questionnaires were printed by the HCP to serve as a 
back-up to secure primary outcome measures. Data management plans (DMP) for first visit 
and follow-up were produced. Data cleaning was securely performed by members of the 
research team together with independent statisticians from a statistical agency (the same 
agency that performed sample size calculation and randomization). 
5.5.13 Analyses 
The intervention effect was estimated by using logistic mixed effects models (including 
covariates known to affect contraceptive choice) with random intercept for clinic to account 
for clustering. To measure intervention differences by clinic type, we assessed the treatment 
effect for each clinic type separately. ICC estimates and their 95% confident intervals were 
calculated using the random intercept logistic model ICC from Wu, Crespi & Wong (117). A 
two-sided p-value of less than 0.05 was considered statistically significant. Secondary 
outcomes were analysed with logistic mixed models, including clinic as random effects and 
intervention and clinic type as fixed effects. Data analyses were performed in SPSS version 25 
and R version 3.6.0. For more details, please see the appended manuscript (paper III).   
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Chi-square tests and Fisher’s exact tests were used to analyse proportions of user satisfaction. 
A one-sample Kolmogorov-Smirnov test was used to analyse the HCPs’ estimation on time 
consumption.   
5.6 REFLECTION AND ETHICAL CONSIDERATIONS 
All studies in this thesis received ethical approval by the regional ethical review board in 
Stockholm, Sweden: 
Study I – Dnr 2013/2069-31/1, amendment (increased number of participants to account for 
loss to follow-up) 2014/1805-32. 
Study II – Dnr 2013/1514-31/4, amendment 2016/543-32. 
Study III – Dnr 2017/525-31/4, amendment 2018/940-32 and 2019-00931. Approval for 
conducting the study at clinics within SLSO was also obtained (SLSO-1545).  
All subjects were given verbal and written information about the studies before signing 
their informed consent for study participation. Furthermore, all patients were informed that 
participation was voluntary and that withdrawal was to be accepted at any time without 
affecting the current or future treatment and healthcare. They were also informed that 
declining participation would mean that they received standard care according to today’s 
clinical routine.  
In research ethics, a principle of equity of study participants is constant. All studies in this 
thesis evaluate treatment and interventions that are assumed to be beneficial for participants 
in one of the two groups. However, the other subjects receive standard care or treatment 
with placebo, which constitutes very little discomfort. Hence, study participation is of no 
harm to any subjects. In the broader perspective, the overall aim to increase use of LARCs 
should be considered positive for the individual user and the society at large as LARCs lead 
to reduced numbers of unintended pregnancies and abortions.  
For study I, some participants were found eligible for study participation by a screening of 
their most recent sexual history during visits for sexually transmitted infection testing. They 
were then informed about their risk of unintended pregnancy if they reported unprotected 
sexual intercourse. Women received structured counselling about EC regardless of the 
reason for the visits. Before the start of the study, this was considered a risk of increased 
levels of anxiety among those that were unaware of their risk. However, to give EC 
counselling to women in need is considered best practise, especially since previous study 
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findings have shown low use of EC among women seeking abortion care services. All study 
participants received the same structured counselling and were offered or prescribed EC 
according to preference. Eligible participants were counselled by all midwives employed at 
the clinic during the study period. These midwives also performed the IUD insertions and 
data collection at first visit. This methodology may increase the risk of biased information 
due to a wish to please the provider because of a provider-patient relationship (112).  
For study II, the intrauterine instillation required an additional waiting time of five minutes 
between administration and insertion of the IUD. Since this waiting time had to be spent in 
the lithotomy position, it could be experienced as unnecessary and unpleasant. Risk of 
adverse events related to the intervention was assessed as minimal since no sharp objects 
were to be used and that the study drug was to be administered inside the uterine cavity and 
not injected in any tissue. The use of mepivacaine did not require any specific actions to 
prepare treatment of any adverse events since the risk of allergic reactions was assessed as 
minimal. Participants randomized to intervention could benefit from less pain during 
insertion if mepivacaine proved to be effective. Finding a non-invasive and effective 
method for pain management during IUD insertion could lead to increased uptake of IUDs 
since the fear of pain barrier could be removed. 
For study III, patients were informed about the study either in a private room or in the 
reception area/waiting room. Due to the interior design of some participating clinics, study 
information could not be given in an entirely private area which could be found stressful by 
the patient. In addition, most MHCs provide contraceptive counselling as a drop-in service, 
and the waiting room was often crowded with other patients resulting in a cramped and 
noisy space. To receive study information and to fully comprehend the meaning of study 
participation, under those circumstances, could be difficult. However, the experience from 
HCPs and study staff recruiting participants in those clinics was that patients were more 
likely to decline rather than accepting participation under those circumstances. Participants 
recruited from clinics randomized to intervention received structured contraceptive 
counselling with an emphasis on the effectiveness of LARCs. They were asked questions 
about how they would react to an unintended pregnancy, for how long they needed their 
contraception, and how much pain and bleeding they experience during menstruation. 
These questions could be found intrusive if your initial intention for a visit was a 
prescription renewal.  
Risk of higher rates of contraceptive drop out among users that have not been fully 
involved in the choice of method has been discussed. However, study findings can be 
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interpreted as the method started is the only predictor for high continued use, all in favour 
of LARCs above other methods (19-21). In this study, the intervention could be considered 
beneficial over standard care since it means that participants in the intervention arm most 
likely will receive a more comprehensive contraceptive counselling. However, to include 
standard care in clinical trials is not unusual, and this was not considered an ethical obstacle 
as participants from clinics randomized to control received standard care. 
For study III, paper IV, no other ethical considerations concerning study participants, apart 
from those raised above, were taken into account. To evaluate user satisfaction with the 
received intervention, especially without the presence of the provider, could not be seen as 
intrusive or to come with a risk of biased information. However, this study also analyses 
user satisfaction from the HCP’s perspective. Invitations were sent to providers that had 
delivered the intervention. To receive a questionnaire to your work or private email address 
could come with a feeling of being “controlled”. On the other hand, to not evaluate the 
intervention from a provider’s perspective could also be considered unethical. The 
providers invested work into delivering the intervention and could be considered to have 
the right to raise their opinion about feasibility if the intervention were to be implemented 
as part of their future clinical praxis.   
There were no financial incentives for any study participants in the thesis, and costs for any 
contraception had to be paid for by the participant unless covered by existing subsidies. 
Clinics participating in study III received a small compensation of €2 for each recruited 
participant, but no individual reimbursement was given to HCPs for contributing to 








6.1 TABULATED OVERVIEW OF MAIN RESULTS 
This table contains the main results of the different studies within this thesis. A summary of 
the findings related to each study specific research questions are presented under the 
following subheadings. More details are found in the appended reprints of Papers I–IV.   
Table 5. Overview of study objectives and finding 
 Objectives Main results 
Study I, 
Paper I 
To compare use of an effective method 
of contraception 6 months following 
insertion of a copper intrauterine device 
or intake of ulipristal acetate for 
emergency contraception. 
Participants opting for a Cu-IUD for EC were using 
effective contraception at 6 months follow-up to a 




To evaluate whether intrauterine 
mepivacaine instillation before 
intrauterine device insertion decreases 
pain compared to placebo. 
In the ITT-analysis, intrauterine mepivacaine instillation 
did not decrease pain scores with IUD insertion 
compared to placebo.  
The PP-analysis showed a decrease in pain scores with 
IUD insertion. 
More participants receiving mepivacaine experienced 
insertion as easier than expected or as expected 





To evaluate the effect of structured 
contraceptive counselling on LARC 
uptake, LARC initiation and pregnancy 
rates in abortion clinics, maternal health 
clinics and youth clinics. 
More participants receiving structured contraceptive 
counselling chose/received a prescription of LARCs 
compared to standard contraceptive counselling.  
Structured contraceptive counselling was associated 
with higher LARC initiation at three months follow-up 





To evaluate user satisfaction of 
healthcare providers and participants 
with an intervention used in a cluster 
randomized trial and to characterize 
which providers and receivers found the 
intervention most helpful. 
Both HCPs and participants reported high satisfaction 
with the intervention used in the trial.  
HCPs reported use of the study intervention to be time 
neutral compared to standard contraceptive counselling.  
No certain identifiers of satisfaction could be 
determined among HCPs 
More migrant and 2nd generation migrants than non-
migrants found the educational video to be supporting 
contraceptive choice comped to  
 
6.2 IS INSERTION OF CU-IUDS FOR EMERGENCY CONTRACEPTION AN 
EFFECTIVE WAY TO INCREASE SUBSEQUENT USE OF EFFECTIVE 
CONTRACEPTION? STUDY I, PAPER I 
Participants were recruited from February 2014 to January 2015. Out of 101 women who 
were invited to participate, 22 declined. The majority of these women chose UPA for EC. A 
total of 39 women were recruited in the UPA group, and 40 women were recruited in the 
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Cu-IUD group. Four women were lost to three months follow up in the Cu-IUD group 
whereas seven and eight were lost to three months and six months follow-up in the UPA 
group, respectively. Analyses for the secondary outcomes (3 months follow-up) and the 
primary outcome (6 months follow-up) included 68 and 67 women, respectively. The flow 
chart is available in the appended reprint of paper I.  
No insertion failures nor any expulsions were reported during the study period. Mean age 
differed between groups with women being significantly older in the Cu-IUD group 
(p=0.004). Baseline characteristics are presented in table 6.  
More women in the Cu-IUD group were using an effective contraceptive method at three 
and six months follow-up (table 7). LARC use at six months follow-up was higher in the 
Cu-IUD group compared to the UPA group (p<0.001). A figure presenting all contraceptive 
methods used by participants at first visit, at 3 months and at 6 months follow-up is 
available in the appended reprint of paper I.  
In the Cu-IUD group, one participant had her IUD removed due to suspected infection, and 
one was accidentally dislodged during cervical cytology testing. Continued use of Cu-IUD 
after three and six months was 35/37 (94.6%) and 28/36 (77.8%), respectively. Method 
acceptability was high, with most women rating the insertion procedure as easier than 
expected or as expected (24/35, 68.6%). In addition, 31/36 (86.1%) stated that they would 
recommend the Cu-IUD for EC to a friend. 
Numbers of women reporting subsequent UPSI within the follow-up period were 4/36 
(11.1%) in the Cu-IUD group compared to 14/31 (45.2%) in the UPA group (p=0.02). The 
patient who had her IUD removed due to infection started COC, which failed and was 
pregnant at three months follow up. There were four pregnancies in the UPA group, out of 
which three were terminated, and one continued.  
The most pronounced reason for not choosing the Cu-IUD for EC was fear of pain during 
insertion (30.3%, 10/33).  
No adverse events during IUD insertion were reported.   
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Table 6. Baseline characteristics by study group 
 Cu-IUD UPA p-valuea 
Age  27 (20–40) 24 (18–38) 0.004 
Parity  0 (0–3) 0 (0–1) 0.405 
Previous abortion 0 (0–1) 0 (0–1) 0.948 
Data are median (range). 
aMann-Whitney U-test 
Cu-IUD, copper intrauterine device; UPA, ulipristal acetate 
 
 
Table 7. Use of effective contraception at 3 and 6 months after Cu-IUD or UPA for emergency contraception. 
 Effective method No effective method Missing p-value 
3 months 
Cu-IUD 35/36 (97.2%) 1/36 (2.8%) 4 <0.001 
UPA 19/32 (59.4%) 13/32 (40.6%) 7 
6 months 
Cu-IUD 30/36 (83.3%) 6/36 (16.7%) 4 0.03 
UPA 18/31 (58.1%) 13/31 (41.9%) 8 
aFisher’s exact test. 
Cu-IUD, copper intrauterine device; UPA, ulipristal acetate 
 
6.3 DOES INTRAUTERINE INSTILLATION OF MEPIVACAINE DECREASE 
PAIN WITH IUD INSERTION IN NULLIPAROUS WOMEN? STUDY II, 
PAPER II 
Participants were enrolled from November 2013 to May 2017, with the last follow-up 
contact in November 2017. Out of 105 patients assessed for eligibility, 19 were excluded, 
and 86 (82%) were randomized. A total of 81 and 78 women were included in the ITT and 
PP analysis, respectively.  The flow chart of participants is available in the appended reprint 
of paper II.  
Baseline characteristics and type of IUD inserted for the 41 women in the intervention 
group, and the 40 in the placebo group are detailed in table 8. In the ITT analysis, pain 
scores with IUD insertion was 1.1 cm less in the intervention group compared to the 
placebo group (4.8 vs 5.9). Among pain scores for all procedure steps, the difference with 
sounding reached 1.5 cm between the groups (p=0.048). More women receiving the 
intervention reported the IUD insertion to be easier than expected or as expected compared 
to women receiving placebo, and fewer women reported it as worse than expected. Exact 
figures on the primary and secondary outcomes measured at the first visit are presented in 
table 9.  
 
 41 
In the PP analysis, the median pain score with IUD insertion was 4.8 (IQR 3.1–5.5) in the 
mepivacaine group compared to 6.0 (IQR 3.4–7.6) in the placebo group (p=0.033).  
No significant differences between groups were found with regards to acceptability of 
method for pain relief, continued use of IUD, opting for another IUD in the future and 
recommendation of IUD to a friend. Overall, 75 (92.6%) study participants reported that 
they would recommend the intrauterine instillation for pain relief to a friend. 








Table 8. The baseline characteristics and type of IUD of study participants by analgesia used before IUD insertion. 
 Mepivacaine (n=41) Placebo (n=40)  
 Median IQR Median IQR P* 
Age (years) 22 19.5–25.5 22 20–25.8 0.835 
Usual period cramping (VAS) 4 2.4–6.1 3.2 2–6.5 0.674 
Previous Medical Abortion 6 (14.6) 5 (12.5) 1 
Previous Surgical Abortion 1 (2.4) 3 (7.5) 0.36 
Previous IUD insertion 7 (17.1) 6 (15) 1 
Type of inserted IUD 
   LNG-IUS 52 mg 20 (48.8) 18 (45) 0.82 
   Copper-IUD 12 (29.3) 11 (27.5) 0.29 
   LNG-IUS 13.5 mg 3 (7.3) 14 (35) 0.62 
   LNG-IUS 19.5 mg 1 (2.4) 0 (0) 1 
All data are presented as median, interquartile range and n (%). 
IQR, interquartile range; VAS, visual analog scale; IUD, intrauterine device; LNG-IUS, levonorgestrel releasing 




Table 9. The primary and secondary outcomes during and after IUD insertion by analgesia used before the procedure 
 Mepivacaine  (n=41) Placebo (n=40) pa 
 Median IQR Median IQR  
VAS 
Baseline pain 0 0–0.2 0 0–0.1 0.734 
Instillation of study drug or placebo 1.4 0.8–2.9 2.2 0.3–3.5 0.319 
Tenaculum 2.2 0.9–3.4 2.4 0.3–4.5 0.487 
Sounding 3.4 1.7–5.9 4.9 2.6–6.6 0.048 
IUD insertion 4.8 3.1–5.8 5.9 3.3–7.5 0.062 
Before leaving the clinic 1.3 0.5–2.5 1.3 0.6–3.7 0.545 
Overall experience of IUD insertion 
Easier than expected 26 (63.4) 15 (37.5) 0.006b 
As expected 12 (29.3) 11 (27.5) 
Worse than expected 3 (7.3) 14 (35) 
*Two group comparison using independent sample t-test and Mann-Whitney U-test where appropriate 
All data are presented as median, interquartile range and n (%). 
IQR, interquartile range; VAS, visual analog scale; IUD, intrauterine device. 
aTwo group comparison using Mann-Whitney U-test. 




6.4 IS STRUCTURED CONTRACEPTIVE COUNSELLING WITH EMPHASIS 
ON METHOD EFFECTIVENESS AN EFFECTIVE WAY TO INCREASE 
LARC UPTAKE? STUDY III, PAPER III 
A total of 28 clinics were randomized and included in the analysis. Mean cluster size was 47 
with a variation from 11–60 recruited participants. Baseline characteristics of clinics are 
presented in table 10. 
From Sept 2017 to May 2019, a total of 1359 patients were enrolled. The analysis of the 
primary outcome included 1338 participants. The loss to follow-up, including withdrawals 
was 19.6% (129/658) in the intervention group and 21.9% (149/680) in the control group, 
leaving 1058 (79.1%) to be included in the analyses of the secondary outcomes. The study 
flow of clinics and participants is available in the appended paper III.  
Groups differed with a lower proportion of participants in the intervention group who had 
experienced a vaginal birth or with current or most recent use of LARC. Baseline 
characteristics of participants are presented in Table 11.  
More participants in the intervention group chose/received prescriptions of LARCs after 
counselling compared to the control group. Table 12 presents the result of the mixed model 
analysis on the intervention effect in total and for each clinic type as subgroups. The 
estimated intraclass correlation was 0.01 (95% CI, 0.00–0.05).  
Intended LARC use prior to counselling did not differ between intervention and control 
groups. For participants without intended LARC use, the post-counselling proportion of 
participants choosing LARCs was higher in the intervention group (145/523, 27.7%) 
compared to the control group (66/513, 12.9%, OR 3.02, 95% CI 2.14–4.28).  
LARC initiation at the three months follow-up was higher among participants in the 
intervention group (213/528, 40.3%) than in the control group (153/531, 28.8%, OR 1.74, 
95% CI 1.22–2.49). Within the 3 months follow-up period 6/527 (1.1%) and 16/531 (3%) 
participants had experienced a pregnancy in the intervention and control group, respectively 
(OR 0.38, 95% CI 0.08–1.68).  
For more details, please see the appended reprint of paper III.   
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Table 10. Baseline characteristics of clinics 
 Intervention (n=14) Control (n=14) 
Clinic type 
Abortion clinic 2 (50·0%) 2 (50·0%) 
Participants  111 (49·1%) 115 (50·9%) 
Average cluster size* 55·5 57·5 
Youth clinic 6 (46·2%) 7 (53·8%) 
Participants  283 (48·6%) 299 (51·4%) 
Average cluster size* 47·2 42·7 
Maternal health clinic 6 (54·5%) 5 (45·5%) 
Participants  264 (49·8%) 266 (50·2%) 
Average cluster size* 44·0 53·2 




Table 11. Baseline characteristics of participants 
 Intervention (n=658) Control (n=680) 
Sociodemographic characteristics 
Age (years) (n=1338) 
Median (IQR) 24 (20–29) 24 (20–30) 
Current relationship (n=1295) 
Single 181 (28.3%) 167 (25.5%) 
Partner – living together  260 (40.7%) 276 (42.1%) 
Partner – living apart 187 (29.3%) 201 (30.6%) 
Other 11 (1.7%) 12 (1.8%) 
Highest completed education (n=1295)                                         
Primary school  70 (11.0%) 77 (11.7%) 
Secondary school  329 (51.5%) 365 (55.6%) 
College/University  239 (37.4%) 214 (32.6%) 
Unknown   1 (0.2%) 0 (0%) 
Reproductive and contraceptive history 
Current or previous pregnancy (n=1335) 223 (34.0%) 257 (37.8%) 
Nulliparous (n=1332) 538 (82.3%) 531 (78.3%) 
Medical abortion (n=1333) 137 (20.9%) 152 (22.4%) 
Surgical abortion (n=1332) 44 (6.7%) 48 (7.1%) 
Vaginal birth (n=1333) 98 (15.0%) 133 (19.6%) 
Caesarean sectio (n=1333) 29 (4.4%) 40 (5.9%) 
Most recent or current contraception (n= 1289) 
LARC* 77 (12.1%) 111 (17.0%) 
SARC† 357 (56.1%) 358 (54.8%) 
Other‡ 134 (21.1%) 122 (18.7%) 
None  68 (10.7%) 62 (9.5%) 
LARC = long-acting reversible contraceptive *intrauterine device or subdermal implant. 
SARC = short-acting reversible contraceptive †combined pill, progestin only pill, contraceptive injection, 
transdermal patch or vaginal ring. 




Table 12. Primary outcome by clinic type 
 LARC* choice/prescription Intervention effect P-value 
 Intervention 
(n = 658) 
Control 







Total (n = 1338) 267 (40.6%) 206 (30.3%) 1.70 (1.19–2.35)  2.77 (1.99–3.86) <0.001 
Abortion clinic 
(n=226)† 
83 (74.8%) 64 (55.7%) 2.36 (1.34–4.15) 3.37 (1.76–6.47) <0.001 
Youth clinic 
(n=582) 
123 (43.5%) 76 (25.4%) 2.31 (1.48–3.62) 3.31 (2.01–5.46) <0.001 
Maternal health 
clinic (n = 530) 
61 (23.1%) 66 (24.8%) 0.99 (0.53–1.83)  1.92 (1.03–3.57) 0.039 
Models were adjusted for age, highest completed education, previous pregnancy with and without previous 
abortion, intended use of LARCs, and clinic type.  
LARC, long-acting reversible contraceptive; OR, odds ratio 
*Intrauterine contraception or subdermal implant. 
†The model for the abortion clinics was estimated without the random intercept for clinic. All models were adjusted 
for intended LARC use and pregnancy/abortion. 
6.5 HOW DO HEALTHCARE PROVIDERS AND PARTICIPANTS 
EXPERIENCE USE OF THE INTERVENTION FOR STRUCTURED 
CONTRACEPTIVE COUNSELLING AND DO THEY FIND IT TO BE 
SUPPORTIVE IN THEIR COUNSELLING AND CONTRACEPTIVE 
CHOICE? STUDY III, PAPER IV 
Fourteen clinics were randomized to provide the study intervention in contraceptive 
counselling. In the intervention clinics, 1085 eligible patients were invited to participate out 
of which 658 enrolled. Participants were recruited from Sept 2017 to May 2019. The 
flowchart of clinics and participants is available in the appended reprint of paper IV. Among 
HCPs providing contraceptive counselling, 55/62 (88%) completed the electronic survey and 
639/658 (97.1%) participants had data on satisfaction rates. Baseline characteristics of HCPs 
and participants are presented in table 13 and 14. 
Receiver and provider satisfaction with the educational video, the effectiveness chart, and the 
box of contraceptive models are presented in table 15. More migrant and 2nd generation 
migrant participants found the effectiveness chart to be supportive in their contraceptive 
choice compared to non-migrant participants (64.4% and 70.2% vs 54.5%, p=0.028).  
HCPs satisfaction with the key-questions and overall satisfaction with the intervention are 
presented in table 16. Most HCPs would like to use the intervention package in their routine 
counselling (please see the figure in the appended reprint of paper IV). More HCPs working 
at maternal health care clinics were less satisfied with the intervention as a whole compared 
to HCPs working at youth- or abortion clinics (p=0.025).  
A discrepancy between the proportion of HCPs reporting full intervention adherence (96.5%, 
632/655) and the proportion of participants reporting having received all parts of the 
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intervention was present, with 10.3% (66/638) not shown the effectiveness chart and 19.1% 
(122/639) not shown the box of contraceptive  
HCPs assessed the use of the intervention outside the study to be time-neutral compared to 
routine counselling (median 0, IQR -5 to 5). HCPs believed that that the intervention affected 
the patients’ contraceptive choice to a large extent (70.9%, 39/55) or some extent (18.2%, 
10/55).  
For more details, please see the appended reprint of paper IV. 
Table 13. Baseline characteristics of healthcare providers. 
Age group (years), n=55 
20–29 2 (3.6) 
30–39 10 (18.2) 
40–49 21 (38.2) 
50–59 10 (18.2) 
³60 12 (21.8) 
Clinic type  
Abortion clinic 11 (20.0) 
Youth clinic 19 (34.5) 
Maternal health service 25 (45.5) 
Occupation 
Medical doctor 4 (7.3) 
Midwife 51 (92.7) 
Work experience within occupation (years) 
1–2   5 (9.1) 
3–4 1 (1.8) 
5–9 15 (27.3) 
10–14 9 (16.4)  
15–19 5 (9.1) 
³20  20 (36.4) 
Work experience of contraceptive counselling (years) 
0–2 10 (18.2) 
3–4 7 (12.7) 
5–9 11 (20.0) 
10–14 10 (18.2) 
15–19 9 (16.4) 
³20 8 (14.5) 





Table 14. Baseline Characteristics of participants. 
Age, median (IQR) , n=658 24 (20-29) 
Highest completed education, n=639 
Elementary school 70 (11.0) 
High school  329 (51.5) 
College/University  239 (37.4) 
Unknown 1 (0.2) 
Foreign background, n=638  
Non migrant 490 (76.8) 
Migrant 90 (14.1) 
2nd generation migrant 58 (9.1) 
Reproductive and contraceptive history  
Ever pregnant, n=656 223 (34.0) 
Nulliparous, n=654 538 (82.2) 
Abortion, n=655 166 (25.3) 
Most recent or current contraception, n=636 
LARCa 77 (12.1) 
SARCb 357 (56.1) 
Otherc 134 (21.1) 
None  68 (10.7) 
Clinic type, n=658 
Abortion clinic 111 (16.9) 
Youth clinic 283 (43.0) 
Maternal health clinic 264 (40,1) 
Data are n (%) unless stated otherwise. IQR, Interquartile range; LARC, long-acting reversible contraception; 
SARC=short-acting reversible contraception. aintrauterine device or subdermal implant. bcombined pill, 
progestin only pill, contraceptive injection, transdermal patch.ccondom, diaphragm, smartphone application, 





Table 15. User satisfaction with intervention parts by healthcare providers and participants. 







Educational video  
Very good  25 (45.5) 378 (57.4) 19 (2.9) 0.09 
Good 27 (49.1) 230 (35.0) 0.04 
No opinion 3 (5.5) 28 (4.3) 0.5 
Poor 0 (0) 3 (0.5) 1 
Very poor 0 (0) 0 (0)  
Video was supportive in 
contraceptive counselling/choice 
41(74.5) 431 (65.5) 19 (2.9) 0.19 
Effectiveness chart  
Very good 32 (58.2) 318 (48.3) 20 (3.0) 0.16 
Good 20 (36.4) 221 (33.6) 0.77 
No opinion 2 (3.6) 33 (5.0) 1 
Poor 1 (1.8) 0 (0)  
Very poor 0 (0) 0 (0)  
Effectiveness chart was supportive 
in contraceptive counselling/choice 
52 (94.5) 355 (54.0) 37 (5.6) <0.001 
Box of contraceptive models  
Very good 31 (56.4) 292 (44.4) 19 (2.9) 0.09 
Good 17 (30.1) 177 (26.9) 0.53 
No opinion 7 (12.7) 48 (7.3) 0.18 
Poor 0 (0) 0 (0)  
Very poor 0 (0) 0 (0)  
Models were supportive in 
contraceptive counselling/choice 
50 (90.1) 326 (49.5) 39 (5.9) <0.001 
Data are n (%). Significance calculated with Chi-Square and Fisher’s exact test where appropriate. 
Table 16. User satisfaction with intervention parts rated only by healthcare providers 
Key-questions 
Very good 17 (30.1) 
Good 23 (41.8) 
No opinion 11 (20.0) 
Poor 4 (7.3) 
Very poor 0 (0) 
Questions were supportive in contraceptive 
counselling 
41 (74.5) 
Overall satisfaction with intervention  
Very good 21 (38.2) 
Good 29 (52.7) 
No opinion 4 (7.3) 
Poor 1 (1.8) 
Very poor 0 (0) 




This thesis aims to find pathways to increasing uptake of LARC by the use of clinical 
interventions for improved quality of care from both an HCP’s and a patient’s perspective. 
The results show that uptake of LARC can be achieved by emphasizing the effectiveness of 
LARC methods and making provision more acceptable. The findings show that provision 
of Cu-IUDs for EC is an effective clinical routine that increases use of effective 
contraception, and a high proportion of Cu-IUD users would recommend this method of EC 
to a friend. Thereby the use of the Cu-IUD for emergency contraception can be increased, 
and regular use of LARCs for contraception can be achieved in a diverse clinic setting. 
Women’s most frequent reason for not choosing the Cu-IUD was fear of pain during IUD 
insertion, a finding serving as a connecting thread to the second trial in the thesis. 
Intrauterine mepivacaine prior to IUD insertion did not prove to be as effective in reducing 
pain as anticipated but positively affected the experience of the insertion procedure. The 
results show that a highly acceptable method for pain relief resulted in significantly fewer 
women experiencing the IUD insertion as worse than expected, and such a method for pain 
relief could increase the use of IUDs for contraception. 
Furthermore, the findings demonstrate that structured contraceptive counselling consisting 
of different counselling tools increases uptake of LARCs, hence contributing to a lower risk 
of subsequent unintended pregnancies. Finally, our findings prove that structured 
contraceptive counselling has high acceptability both among patients receiving it and 
among HCPs providing it. The different studies all contribute to increasing access and 
uptake of LARC. 
7.1 CU-IUDS FOR EMERGENCY CONTRACEPTION 
Most clinicians know that the Cu-IUD is the most effective method for EC and that IUDs 
can be promoted to nulliparous women. Despite this, few service providers offer IUDs as 
EC for women (58-60). Hence, our study of Cu-IUD compared to UPA for EC according to 
the users’ preference is important for the provision of arguments to increase access to- and 
uptake of LARCs for women who need EC. It is the first study of its kind in a Swedish 
setting. The results are of great value since they fill the knowledge gap about reasons for 
not choosing the most effective method even though it is clearly recommended by the HCP, 
and offered free of charge. The results also strengthen previous findings of fear of pain as a 
barrier to uptake of IUDs (118, 119). At follow up 3 women in the UPA group had initiated 
LARC use—2 Cu-IUDs and 1 LNG-IUS. This could be by chance, but it is also likely that 
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the counselling about IUDs as the most effective method contributed to the decision to have 
one inserted in a later stage. The only pregnancy in the Cu-IUD group occurred after IUD 
removal and subsequent failure with oral contraception. All three women who experienced 
a pregnancy had an abortion within the follow-up period. This finding support previous 
findings that the method for contraception is the most important factor influencing future 
risk experiencing an unintended pregnancy (19-22).      
7.2 PAIN MANAGEMENT DURING IUD INSERTION 
A common misconception is that young women and those without previous experience of 
vaginal delivery are not good candidates for IUDs. With regard to the relative effectiveness of 
LARCs to other less user-friendly methods, especially among young women (14), nulliparous 
women are excellent candidates for IUDs. IUDs are currently recommended as first-line 
contraception for young women (120-122). Nulliparity is, however, one factor that increases 
the risk of painful insertion (68, 83), and finding an effective and well-accepted method for 
pain relief in this patient group has previously failed. Although it has been shown that young 
and nulliparous women accept IUD insertion well, reporting mild to moderate pain 
experience with the procedure (74, 123), there is an urge to find a truly effective method since 
the fear of pain during insertion still limits the uptake of IUDs (66-70). Sounding is included 
as a standard routine in the insertion procedure and is well known to cause discomfort and 
pain (78). In our study population, the pain experienced during sounding differed 
significantly between intervention and placebo. All insertion procedures could add up and 
affect the total experience of the insertion. Thus, this finding is relevant. However, IUDs can 
be safely inserted in most women without sounding (80), making this secondary outcome less 
relevant than insertion pain score. The findings in this thesis show that nulliparous women 
treated with intrauterine mepivacaine prior to insertion had rather low pain scores (median 
4.8), but also that the treatment was associated with a better total experience of the insertion. 
No clinically significant pain reduction cutoff has yet been established. Problems with using 
VAS for measuring pain perception is further elaborated in the following section of 
methodological considerations. As explored in the review part of the thesis, some effective 
methods are painful to receive or cause discomfort to the receiver (88, 124). It could be 
argued that a method for effective pain relief has to be somewhat pain-free to receive to be 
acceptable. Participants in our study reported low pain scores with intrauterine installation—
1.4 and 2.2 in the intervention and placebo groups respectively—and most women (92.6%) 
would recommend this method for pain relief to a friend. These findings suggest that this 
method for pain relief is highly acceptable to patients.    
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Future studies of intrauterine mepivacaine are of interest and planned, and if found effective, 
it could be an important method used to address women with fear of pain and hence 
increasing uptake of IUDs. 
7.3 STRUCTURED CONTRECEPTIVE COUNSELLING  
Despite easy access to contraception, Swedish women have a low uptake of effective 
contraception in comparison to other high-income countries (12). One possible explanation 
is that Swedish women are afraid to use hormonal contraception resulting in use of less 
effective methods for contraception such as safe periods, condoms and 
withdrawals/interrupted intercourse (16, 17). This has led to high rates of unwanted 
pregnancies and abortions, and it could be argued that the Swedish model needs 
improvement.  
Our intervention package for structured contraceptive counselling included an educational 
video with information about contraceptive methods with an emphasis on method 
effectiveness. The use of educational videos as intervention parts has been evaluated by 
other researches, finding it to increase method-specific knowledge (125, 126) and affect 
contraceptive choice toward use of more effective contraceptive methods (98, 125). Our 
findings support the use of video as a supporting media prior to contraceptive counselling 
since it increases uptake of the most effective methods and has high acceptability both 
among HCPs and patients.  
The use of contraceptive models in counselling makes women more aware of their actual 
size and route of administration, which might lead to finding them smaller and less 
frightening than imagined (119). A vast majority (80%) of HCPs found the box of 
contraceptive models to be very supportive in their contraceptive counselling. 
Approximately 50% of the participants found the box of models to be supportive in their 
contraceptive choice. However, 10% were never shown the models, and another 5% did not 
evaluate this part of the intervention. Altogether, these finding supports the use of models 
during counselling to improve uptake of LARCs.  
The use of tiered charts to communicate contraceptive effectiveness has proven to increase 
method-specific knowledge and to increase uptake of LARCs (116, 127, 128). The 
effectiveness chart used in our intervention was modified to present differences between 
contraceptive methods both in pregnancies per year among 10 000 users and effectiveness 
in per cent. This dual presentation was chosen to reach women who find it easier to 
overlook the differences presented in either numbers or proportions. Different designs were 
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piloted among HCPs and lay-people before the final version was set. This approach was 
evidently effective since the effectiveness chart received high satisfaction rates from both 
HCPs and participants, and was found to be supportive in contraceptive counselling 
(94.5%) and choice of contraceptive method (54.0%). This was the part of the intervention 
that most HCPs wanted to continue to use in their future routine counselling (90.9%).  
Our intervention included key-questions. They were intended as counselling catalysts, to 
make women reflect about how to deal with pregnancy, for how long contraception was 
needed, but also to catch information about menstrual bleeding and cramping. The use of 
One Key Question® has been proven to increase the proportion of women receiving 
contraceptive counselling within primary care settings (129). The key-questions used in our 
intervention received high satisfaction rates, and they were also found to be supportive in 
contraceptive counselling by 74.5% of the HCPs. The HCPs in our trial are as such trained 
in contraceptive counselling, and more than 80% of the HCPs had 3 or more years work 
experience of providing contraceptive counselling. These findings demonstrate that our 
intervention could also be used in other clinical settings that generally do not actively 
provide contraceptive counselling. From a cost perspective, this could save societies money 
by task-sharing between specially trained contraceptive counsellors and other clinicians, for 
instance, general practitioners, and by such means increase women’s access to facts-based 
information and contraceptive counselling.  
Findings from this thesis demonstrate that women without intended LARC use prior to 
counselling have a higher uptake of LARCs if they receive structured contraceptive 
counselling. The intervention, with evidence-based information about health benefits with all 
contraceptive methods and key-question to address specific health issues that might be helped 
by the use of a certain method, might, of course, result in choice and initiation of another 
method than a LARC method. Inevitably, some women who intended to use LARCs would 
not be suitable for these methods. Although the counselling was intended to increase LARC 
use, this was only the intention in women where LARC use was suitable. 
7.4 MYTHS AND MISCONCEPTIONS 
LARC methods are surrounded by myths and misconceptions. During contraceptive 
counselling, it is common to meet patients who believe that IUDs cause abortion, pelvic 
inflammatory disease and infertility. Some also believe that LARCs cause ectopic 
pregnancies as well as weight gain and acne. Common myths and misconceptions among 
HCPs include that adolescents prefer to use condoms or pills, that parental consent is required 
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prior to LARC provision and that threads of IUDs must be checked regularly. All these myths 
and misconceptions are conclusively proven false in a review by Russo et al. (130). The 
findings from this thesis show that LARCs are highly acceptable methods with high 
continuation rate and proportions of participants recommending LARC use to a friend. 
Effective clinical interventions to increase the uptake of long-acting reversible contraception. 
The video prior to the counselling addressed all myths and misconceptions about 
contraceptive methods which may have affected contraceptive choice. However, addressing 
these myths and misconception among women who are not using contraception remains a 
challenge. 
7.5 INCREASING ACCESS TO AND UPTAKE OF LARCS 
Studies in Sweden show contraceptive use among young women has increased thanks to the 
subsidy system. However, the cost is not an important factor affecting women’s contraceptive 
choices (131) and that few women would change their method of contraception if they were 
all available free of charge (16). However, LARCs have a higher upfront cost than other 
contraceptive methods, and removing the cost-barriers has proven to increase the use of 
LARCs in low resource settings resulting in a reduction of unintended pregnancies (132, 
133). Sweden has adopted a subsidy system allowing almost all contraceptive methods free of 
charge to women below 21 years, and a low cost (approximately €10/year) for women up to 
the age of 26. This might be reflected in the responses of costs not being a factor influencing 
contraceptive choice. Although the recent trend is upwards regarding LARC use in Sweden, 
use of LARCs are still low and, in addition, the trend is pointing in a negative direction 
regarding the use of other contraceptive methods. In 2017 as compared to 2013, more women 
had an unmet need for contraception (17). The most recent national statistics show a decrease 
in abortion rates among teenagers and young women up to 29 years of age (134). This could 
be explained by the increased use of LARCs within these age groups (17). However, this 
positive trend might be changing in the nearest future since more women today rely on no 
method at all compared to 2013 figures (16, 17). Women in the older age groups, 30-39 
years, where the most pronounced decrease in use of contraception is seen, are also having 
increasing numbers of abortions (134). 
Apparently, we need to move forward and increase contraceptive use overall in addition to 
using more effective methods. The findings from this thesis will serve as successful examples 
of what can be achieved with evidence-based information and provision of structured 
contraceptive counselling and focus on the most effective contraceptive methods. The next 
step in Sweden, apart from changing counselling routines within clinics, would be to 
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implement same-day, also known as streamlined provision of IUDs and contraceptive 
implants, which is not the case in most clinics today. Studies have found that multiple visits 
to receive IUDs or implants are a barrier to LARC uptake (135-137). Another follow-up 
study using the Contraceptive CHOICE model for contraceptive counselling, including same-
day insertion, led to higher uptake of LARCs (138). Same-day insertion of LARC is 
considered best practice (139). Efforts have to be made in reducing barriers to streamlining 
insertion, such as rapid pregnancy tests, more time for each patient, insertion prior to 
receiving results from STI tests and increasing method-specific knowledge and insertion 
skills, as these have been shown to often limit the access (62, 98, 128).   
7.6 INCREASING USE OF CONTRACEPTIVE IMPLANTS 
The contraceptive implant is the most effective contraception available, with a PI of 0.05 
(140). Worldwide use is a mere 0.7% compared to the use of IUDs that constitute 14%. 
Thereby both the implant and IUDs are considered underutilized methods (12). It is often 
stated that the negative side effects of the implant, such as prolonged or irregular bleeding are 
unacceptable to the user. This statement is not justified, since the 12-month continuation rate 
of the implant is 84%, equivalent to the continuation rate of IUDs (105). In addition to its 
high effectiveness and high continuation rate, the implant is effective in reducing 
dysmenorrhea caused by endometriosis (141). Based on these findings, it becomes clear that 
the implant is a neglected option for many women and should be promoted to a greater 
extent. Women have been shown to have preprocedural anxiety regarding implant insertion 
(142), something that needs to be addressed during contraceptive counselling. However, a 
counselling argument to make more women consider implants for contraception could 
actually be that the implant insertion comes with less pain than the insertion of an IUD (142) 
a factor that might influence the likelihood to opt for another device in the future. Also, 
candidates should be informed that there is effective pain relief at hands for the inserter.   
7.7 PROVIDER BIAS AND CONSCIENTIOUS OBJECTION 
In the online LEXICO English dictionary, bias is defined as “Inclination or prejudice for or 
against one person or group, especially in a way considered to be unfair”(143). The definition 
of provider bias varies in the literature. A review of provider bias in family planning 
concludes that it includes denying access to contraceptive methods due to prejudice, 
discouraging use of specific methods due to incorrect medical rationale, inadequate technical 
skills or personal beliefs of the provider (144). Provider bias is considered an important type 
of medical barrier since it might include scientifically unjustified medical rationales. It affects 
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the way providers present and recommends contraceptive methods (145). Since trained HCPs 
give contraceptive counselling, the information must not be affected by their personal beliefs 
and/or lack of method-specific knowledge. As method use is vigorously affected by provider 
bias (145), our intervention for the provision of evidence-based structured contraceptive 
counselling targets this risk by reducing differences in the information provided during 
contraceptive counselling. It also targets the risk of women being exposed to incorrect 
medical rationales or unfair prejudice by HCPs. Removing provider bias enables informed 
choice about contraceptive use, in many family planning programs used as a guiding 
principle (144).  
Access to EC is not only affected by factors such as over the counter availability of ECPs in 
pharmacies and access to skilled IUD inserters for obtaining Cu-IUDs for EC. The providers’ 
definition of when the pregnancy actually occurs might also affect the counselling and 
methods for EC that women can access, as well as the sociopolitical context in which the 
provider works. Although the most adopted definition of pregnancy is implantation of a 
fertilized egg in the uterus, some providers interpret the biological process of pregnancy to 
occur at the moment of the sperm fertilizing the egg. In the US, a significant interaction 
between providers definition of the start of a pregnancy to be when the sperm fertilizes the 
egg and practising in areas with high republican vote shares was shown. These providers 
were less likely to provide EC (146). This is a form of provider bias that has to be eliminated 
for women to access high-quality care and a full range of contraceptive methods.  
In Sweden, a case of conscientious objection to providing IUD insertion, EC and abortion 
care has been taken to the industrial court, where the case of a midwife’s right to 
conscientious objection was disliked. The Swedish abortion law does not include the right to 
conscientious objection. This is based on the right of the woman seeking abortion care not 
having to meet these healthcare providers (147). The same kind of arguments has been raised 
in terms of the right to conscientiously deny IUD insertions based on the assumption that it 
will prevent an already fertilized egg from implanting. This type of case was recently 
processed in the higher supreme court in Norway, in which the provider was awarded 
damages from the employer for unjustified reasons for dismissal (148). Norway and Sweden 
are neighbouring countries, and there is a risk that these processes might influence Swedish 
stakeholders. These types of arguments are dangerous to women seeking reproductive health 
care since women with unmet need for contraception are at high risk of unintended 
pregnancies (16, 17, 131) that will affect their social and psychological well-being and 
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economic situation (1-4). Internationally, reproductive healthcare is the only medical field 
that allows HCPs to limit legally regulated access to care by conscientious objection (149). 
To deny reproductive healthcare, such as abortion and contraception, based on arguments of 
“conscientious freedom” is more aptly called “dishonourable disobedience”, since it violates 
the woman’s right to lawful healthcare, and passes all the consequences onto the woman 
herself (150). Sweden, Finland and Iceland, as opposed to Denmark and Norway, do not 
allow conscientious objection (149). Sweden has for long been regarded as a country ahead 
of many other countries in terms of gender equity, which is probably reflected in the decision 
not to allow conscientious objection. For the sake of women’s and children’s health, I argue, 
that is a line we should defend and keep promoting in our advocacy work.   
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8 METHODOLOGICAL CONSIDERATIONS 
This thesis is based on research with different study methodologies approaching the aim from 
different perspectives, including prospective observational analyses from cohorts as well as 
individual and cluster randomized trial analyses. Including opinions from both HCPs and 
patients gives us a broader picture of the feasibility of the clinical routines and interventions. 
Different study designs contribute to elucidating the clinical problems at hand from different 
angles. These methodologies have their inherent strengths and limitations which need to be 
taken into account. When evaluating study findings, it is important to assess the risk of biased 
study results. Bias is defined as “Any process at any stage of inference which tends to 
produce results or conclusions that differ systematically from the truth” (151). 
8.1 STUDY I, PAPER I 
8.1.1 Design 
Observational prospective cohort studies do not include randomization, and the researcher 
does not predefine the exposure status. Instead, the study subjects are observed both 
regarding exposure and outcome. The level of evidence is lower than for an adequately 
powered RCT (152), which could have been another appropriate design for this study to 
improve the external validity (generalizability). However, the results of prospective design 
can be used to asses internal validity (proves causality between exposure and outcome), and 
the results are often reliable (able to be replicated in other studies) (153, 154). A significant 
limitation of this study design is that it requires large sample sizes to detect rare events (155). 
In this study, the sample size was not powered to detect differences in pregnancies, which 
was selected as a secondary, yet important outcome. Another limitation is that it is time and 
money consuming. Two important forms of biases with this study design is selection bias and 
attrition bias (loss to follow-up). Both groups must be selected from the same source of 
population (156). Women loss to follow-up result in missing data and subjects loss to follow-
up may differ from those who are followed for the whole period. Any such differences 
should, if possible, be examined (152). We did not specifically analyze differences between 
women loss to follow up and women who were included in the analysis of primary outcome 
introducing a risk of attrition bias. However, the baseline characteristics did not differ 
between study groups, apart from women opting for Cu-IUD was slightly older (27 vs 24 
years)—a factor introduced in a logistic regression analysis showing no interaction to choice 
om method for EC.  
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8.1.2 Finding eligible participants and recruitment  
The research setting in study I was the RFSU Clinic which provides STI testing in addition to 
contraceptive counselling. During clinic visits, women were screened for UPSI by the use of 
standardized forms for obtaining sexual history. Some women did not have contraceptive 
counselling in mind when first deciding to attend the clinic, and were addressed with the risk 
of unintended pregnancy in case of having had a recent UPSI. They were actively counselled 
about their need for EC, and some women accepted study participation. This way of finding 
eligible patients was successful in terms of rapid enrolment. However, the main reason for 
visiting the clinic was never recorded. In hindsight, that would have been an important factor 
to control for in the analysis of study outcomes since it could have affected the choice of 
method for EC as well as the use of- or continued use of effective contraception. It could also 
have added to the study results if found that women unaware of their risk of unintended 
pregnancy were more likely to choose the less effective method.  
Study information was given from the same contraceptive counsellor who also obtained the 
consent from study participants and provided the method of choice. This methodology adds 
to the feasibility of the study. Both methods were available on-site for immediate provision.  
We had a rather low proportion, 21.8%, of women declining participation. This reduces 
selection bias. However, most women not accepting participation did so based on an 
unwillingness to take extra time to participate in any trials, and most of these women choose 
UPA for EC. These factors might introduce selection bias. The fact that women were not 
randomized might also introduce selection bias, since women opting for a Cu-IUD may have 
been more motivated to initiate effective contraception.   
8.1.3 Follow up 
Follow-up data were mainly collected by a member of the research team who had not been 
involved in any previous patient-related procedures. This approach is suitable to eliminate 
biased information due to social desirability. The data was collected through telephone 
interviews, which proved to be an exhausting and time-consuming process. Getting hold of 
participants from a phone with an unknown or hidden number was difficult, and most patients 




8.2 STUDY II, PAPER II 
8.2.1 Design 
Mepivacaine has not been used in previous research on pain relief with IUD insertion, has a 
low toxicity, and the hydrosonography catheter is easy to access. Hence, the results from this 
study would be of great interest if found effective in reducing pain with IUD insertion. 
The main strength of the study was the use of a double-blinded randomized placebo 
controlled design. Double-blinded RCTs are considered the “Gold standard” for intervention 
trials. The randomization process can eliminate the influence of confounders that might affect 
the outcome, out of which some could be unknown or immeasurable and therefore not 
controlled for in a prospective observational trial. The blinding process eliminates the risk of 
co-variation due to patient’s or HCP’s expectations. The placebo control is important to 
remove the risk of effects on outcomes achieved by the placebo effect and study participation 
as such (154). For randomization, study sites were given blocks of 6-10 numbered envelopes 
containing the study allocation. One clinic started from number zero, and one started at 
number 86. In this way, each clinic inserted the same number of IUDs in the intervention- as 
in the placebo group. Both mepivacaine and placebo (NaCl) are odourless and clear, 
minimizing the risk of unblinding during intrauterine instillation. 
8.2.2 Follow-up 
In this study, the person who collected the follow-up data was blinded to the study allocation 
of the participant. This also reduces the risk of experimenter bias. Also in this study follow-
up was conducted through telephone interviews. To reduce the risk of high loss to follow-up, 
several attempts to reach the participants were made. When finally getting hold of the patient, 
the responses might be affected by a feeling of being chased or just “get it over with”. In 
addition, some participants might have been ashamed for not answering the phone or 
returning the calls. 
8.2.3 Insertion procedure 
All IUDs were inserted following a standardized protocol to limit the risk of differences in 
pain due to differences in insertion procedures. In addition, only one HCPs at the study sites 
performed all the insertions to reduce risk of inter-provider variability.   
8.2.4 Pain assessments   
We did not reach our anticipated difference in VAS pain scores between active treatment and 
placebo. Although validated for measuring procedural pain and widely used in trials, VAS 
 
 61 
could be biased by factors such as a difference in scales used (horizontal, vertical) and 
presentation (description of zero- and top anchor points)(157). During completion of the 
mepivacaine manuscript, we came across different approaches in the use of VAS, for 
instance, used to measure worst pain experienced during a 10-minute period from the actual 
procedure (88) and a 9 point VAS-scale (89). We used the most simple, and commonly used, 
100 mm horizontal VAS and collected our VAS measures immediately after the procedure to 
eliminate the risk of recall bias. However, to compare study outcomes from different studies 
to one another is obviously difficult due to methodology disparities.  
VAS-scales are also more sensitive to small changes as compared to other descriptive ordinal 
scales (157). In our case, the VAS-scores— analyzed with a non-parametric Mann-Whitney 
u-test due to normality violation (158)—had an IQR of 3.1–5.8 cm in the intervention group 
and an IQR of 3.3–7.5 in the control group. The ITT analysis yielded a p-value of 0.062. 
Outliers affected the IQR in a way so that the between-groups difference was 1.1 cm. When 
performing the PP analysis, removing 3 inadvertently included underaged women—which 
happened to include two outliers—and their VAS scores yielded an IQR of 3.1–5.5 in the 
intervention group and 3.4–7.6 in the control group and a between-groups difference of 1.2 
cm. This difference was statistically significant, with a p-value of 0.033. The p-value in the 
PP analysis rejects the null hypothesis that there is no difference in pain reduction between 
mepivacaine and placebo (159).  
However, such small differences might not always be considered clinically significant. In our 
study, we measured total insertion experience with a simpler ordinal scale, including “easier 
than expected, as expected” or “worse than expected”. Testing for differences between our 
intervention and placebo groups, we found that women receiving mepivacaine were less 
likely to have a “worse than expected” experience (p=0.006), which we considered to be a 
more clinically relevant result. Based on this, we argue that the total experience could be of 
higher value than pain scores in VAS when assessing clinical significance in future trials of 
pain with IUD insertion. 
8.3 STUDY III, PAPER III AND IV 
8.3.1 Design  
Cluster randomized trials are different from individually randomized trials. The cluster design 
allows for evaluating intervention effects on a group level and makes more extensive studies 
more feasible with regard to time consumption. In this study, clinics were randomly assigned 
to intervention or control. In addition, to enable testing of our intervention on a large study 
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population, this approach was chosen to eliminate the risk of spillover effects among 
providers working in the same clinics. However, Stockholm is a quite small region, and 
although staff from participating clinics were told not to speak about the study to other 
midwives in the region, this could have happened, resulting in spillover effects.   
8.3.2 Recruitment  
Recruitment of study participants is sometimes hard, especially when there are no obvious 
positive effects that might come from participating. Clinics were informed about the target 
number of patients (50) to recruit at each clinic (cluster size), and that the recruitment period 
was estimated to be 6 months. Clinics that reached the target quickly were encouraged to 
enroll 10 additional patients to adjust for other clinics that did not reach the preferred number 
of participants. This explains the variation in cluster size. At ACs and YCs, most participants 
were recruited by HCPs working at the clinic during scheduled visits, whereas in MHCs, a 
research staff member (mostly myself) had to be present and facilitate recruitment. Letting a 
research team member, not working at the actual clinic, handle the recruitment could lead to 
higher numbers of patients declining participation, which is from one point of view a 
limitation that introduces selection bias. From another point of view, it might be easier for 
women to decline participation since everyone was informed that participation was voluntary, 
and the fact that there was no treater-patient relationship present might reduce social 
desirability bias. 
8.3.3 Randomization and blinding 
Clinics were randomized by a statistician. An attempt to collect baseline prescription of 
different contraceptive methods from participating clinics was performed, but not all clinics 
provided these numbers. However, in addition to clinic type and proportion of migrants 
within the clinic’s catchment area, the numbers we did receive was used to stratify the 
randomization. This was an attempt to make sure that clinics with an already high LARC 
prescription would be evenly distributed between intervention and control arms of the study, 
increasing the external validity of the results.  
Clinics allocation to either intervention or control was blinded up until study start. Then 
HCPs from intervention clinics received study-specific training and therefore blinding past 
this point was no longer possible. 
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8.3.4 Intervention adherence 
There was a discrepancy between HCP-reported intervention adherence (96.5%) and 
participants reporting to have received all parts of the intervention. Participants reported that 
they were not shown the effectiveness chart or the box of contraceptive models in 10.3% and 
19.1% of cases, respectively. This discrepancy might be explained by the fact that women 
were not informed about what parts constituted the intervention. Also, some HCPs reported 
that some women had already decided upon what method to use and therefore were no longer 
open to further counselling as a reason for not showing all intervention parts. Women were 
not asked about adherence to the 4 key-questions as we perceived that they would not be able 
to distinguish these questions from the regular counselling routine. Since the study had an 
intention to treat approach and aimed to catch the true intervention effect in a real-life setting, 
no women were excluded from analysis due to lack of intervention adherence. 
8.3.5 Follow-up 
Prior to enrolment, patients were informed about the follow-up period of 12 months, and that 
they would receive an email with a link to an electronic questionnaire at 3 (paper III), 6 and 
12 months after the first visit. During recruitment, the use of email for follow up applied to 
most participants, however, some would rather receive a telephone call or did not have an 
email address. During follow-up, we noticed that the response rate was not to our satisfaction, 
and the routine was changed to collect both email addresses and telephone numbers to be able 
to call and remind participants to complete the questionnaires or even collect the answers 
over the phone. This increased the response rate, and the final loss to follow-up for paper III 
was 20.9%. In addition to the email approach, in which participants could postpone and 
subsequently forget to complete the follow-up, the large proportion of participants from ACs 
and YCs is seen as explanatory factors since these patient groups usually have a higher loss to 
follow-up rate. 
8.3.6 Analyses and results 
The analyses of data for paper III were performed with help from a statistician. The cluster 
design comes with difficulties in the analysis process due to ICC, a factor that affects p-
values negatively. Our findings are important to share since they might have an impact on the 
Swedish model for contraceptive counselling as well as in other high-income countries. 
Including this kind of study design and such a large trial increases the power of the findings 
of the thesis, and in hindsight overcoming all the obstacles by the help of others shows the 





Use of effective contraception after emergency contraception is higher among women who 
are actively counselled about and offered insertion of a Copper-IUD compared to 
emergency contraceptive pills. Based on the effectiveness, high continuation rate and 
acceptability, providers should promote the Copper-IUD for emergency contraception 
(study I). 
Intrauterine mepivacaine instillation reduced VAS pain scores with IUD insertion by 1.1 
cm in the intention-to-treat population and 1.2 cm in the per-protocol population compared 
to placebo, just below the anticipated difference of 1.3 cm selected for clinical significance 
a priori. Fewer intervention receivers had a “worse than expected” experience of the 
insertion procedure than placebo receivers. A future larger sample size study, with a higher 
potency 2% mepivacaine and the total experience selected as the primary outcome could be 
of interest (study II). 
Structured contraceptive counselling with a focus on effectiveness of contraceptive 
methods results in a higher uptake of LARCs among the participants. The study 
intervention had a highly pronounced effect also in abortion clinics, which has previously 
been difficult to achieve. The vast majority of HCPs and participant were satisfied with the 
intervention and considered it to be supportive in their contraceptive counselling and 
contraceptive choice. The findings imply that structured counselling is an important and 
effective tool which could be easily introduced into several clinical settings. Structured 
contraceptive counselling can affect the uptake of contraception from user-dependent less 
effective methods to LARCs by enhanced informed decision-making, and by such means 
improve the quality of care.   
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10 FROM PATHWAYS TO OPEN FIELDS 
10.1 COMPREHENSIVE SEXUALITY EDUCATION  
As a midwife in one of Sweden’s largest clinics for sexual health, the RFSU Clinic, providing 
services for STI testing and contraceptive counselling as well as psychotherapy, I got to meet 
with a large number of patients who are lacking knowledge about their body, their risks of 
acquiring sexually transmitted infections (STIs) and how to prevent unintended pregnancies. 
RFSU is an important non-governmental organization fighting for sexual and reproductive 
health and rights both in Sweden and internationally. The right to receive facts-based 
information and to choose from a full range of contraception has been the foundation of 
RFSU since it was founded in 1933. In Sweden, all students are entitled to receive sexuality 
education in school. However, from the study findings and clinical experience from the 
RFSU Clinic, it is evident that the quality of this education is highly variable and frequently 
poor—especially with regards to contraception and prevention of STIs. RFSU will keep 
fighting to make Swedish and international politician respect the fundamental rights to 
comprehensive sexuality education and a full range of contraception, including LARCs. 
10.2 CHANGES ARE WANTED, AND NEEDED 
When providing contraceptive counselling for several years at the RFSU Clinic, I 
experienced the lack of time with each patient to limit the possibility to provide 
comprehensive contraceptive counselling. This was even more clear during our drop-in 
clinics. At an early stage, by information gathered from research in the field, I started to use a 
more structured form of counselling. I based it on motivational interviewing and started by 
presenting the most effective methods. Many women expressed that they had never been 
counselled about LARCs before, although some of them had used contraception for many 
years. Most women receive their contraceptive counselling from midwives at MHCs, and 
most counselling is provided during drop-in hours. Although reimbursement from the country 
regions for providing contraceptive counselling is adjusted to allow for approximately 20-
minute sessions, MHCs are often pushed to provide their services within 10 minutes—
sometimes even shorter—to be able to serve all the patients that visit the clinics.  
The waiting rooms are small, and most often so full of patients that there are not enough seats 
for everyone. To see the waiting area cramped with patients causes much stress, and the 
quality in the services provided becomes poor. Strategies to deal with this situation makes 
midwives take shortcuts in their counselling, for instance, by just asking what contraceptive 
method the woman use and if she is pleased with it. If the answer is positive, a quick blood-
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pressure is taken, and a prescription renewal is administered. This type of counselling comes 
with risks of missing essential contraindications. In addition, women are not informed about 
other methods that might be even more suitable. This has traditionally led to high use of less 
effective methods, resulting in numerous of unintended pregnancies and abortions. Women 
want comprehensive information. Women have the right to comprehensive information. And 
more importantly, women need comprehensive information to enhance informed decisions 
about contraceptive use. Introducing structure, with emphasis on method effectiveness in 
contraceptive counselling, improves quality of care. It might also save time. Effectiveness is 
the most important factor expressed when deciding upon contraceptive use, and when 
presented with the most effective methods first, women tend to choose them over less 
effective methods. Thus, much time is saved during this type of counselling since information 
about less effective methods is experienced as redundant by the patient. Another time- and 
money-saving factor is built into the name of LARCs—they can be used for a long time. 
LARCs have high continuation rates, and women using LARCs do not have to pay annual 
visits to clinics for prescription renewals. The thesis findings support the introduction of 
structured contraceptive counselling and provision of Cu-IUDs for EC to increase uptake of 
LARC—and by such means protecting women from unintended pregnancies and subsequent 
abortions. 
10.3 FUTURE RESEARCH 
Based on the study findings, implications for future research has been revealed.  
1. We need to conduct qualitative studies on HCPs experiences with using strutured 
contraceptive counselling to make adjustments to the intervention to increase quality 
even more  
2. We need to do qualitative research with women receiving contraceptive counselling, 
to gain a better understanding about the decision-making process when it comes to 
use of contraception  
3. We need to do research about internet as a source of information about contraception 
4. We need to keep doing research about pain management during IUD insertion, to be 
able to provide women in need with effective pain relief.  
5. We need to conduct implementation research of methods to promote systemic uptake 
of the study findings into routine practice. 
The list could be made longer, but research is time consuming and requires a lot of 




11 SUMMARY  
Unintended pregnancies are an inexhaustible source to life-changing decisions and events 
for individuals and result in enormous costs for societies having to deal with maternal 
health services, deliveries, hospital care and abortions. Unintended pregnancies could be 
prevented by the use of effective contraception and LARC methods, including IUDs and 
implants, have the highest effectiveness, the highest user satisfaction and the highest rates 
of continued use. By increasing uptake of LARC, women would be less exposed to 
mistimed and unwanted pregnancies that are known to affect their social- and psychological 
well-being as well as their economic situation. In addition, societies could save huge 
amounts of money since LARCs are the most cost-effective methods. All money invested 
in preventing unintended pregnancies pays back fivefold.  
Women value the effectiveness higher than any other factor when deciding upon 
contraceptive use, and women want more comprehensive contraceptive counselling than 
HCPs think they do. Comprehensive counselling, especially when given in a structured 
form, result in higher uptake of LARCs, which—in addition to being very effective—also 
are known to decrease other health-related issues such as heavy menstrual bleeding and 
dysmenorrhea. By increasing LARC use, improvements in women’s reproductive health are 
achieved.  
This thesis aims to find pathways to increase uptake of LARC by interventions used to 
improve the quality of care from both an HCP’s a patient’s perspective. The thesis builds 
on one observational cohort study, one double-blinded randomized, controlled trial and one 
cluster randomized trial. All studies were conducted in clinics providing contraceptive 
services in the region of Stockholm, Sweden.  
Study I aimed to compare use of an effective method of contraception 6 months following 
insertion of a copper intrauterine device or intake of ulipristal acetate for emergency 
contraception. The hypothesis was that patients opting for a Cu-IUD would use effective 
contraception at 6 months to a higher extent compared to patients opting for UPA (primary 
outcome). In addition, we hypothesized that participants in the Cu-IUD group would have 
had less unprotected sexual intercourses and fewer pregnancies. The results show that 
participants opting for a Cu-IUD for EC use effective contraception at 6 months follow-up 
to a greater extent than participants opting for UPA. The proportion of women with 
subsequent unprotected sexual intercourse during the follow-up period was lower in the Cu-
IUD group compared to the UPA group. The differences pregnancies, 1 in the Cu-IUD 
group and 3 in the UPA group, did not reach statistical significance.  
Study II aimed to evaluate whether intrauterine mepivacaine instillation before IUD 
insertion decreases pain compared to placebo. The hypothesis was that intrauterine 
mepivacaine instillation would numb the uterine and cervical lining and reduce pain with 
IUD insertion. We also hypothesized that mepivacaine would provide a more effective pain 
relief than saline solution (NaCl). In the ITT-analysis, intrauterine mepivacaine instillation 
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did not decrease pain scores with IUD insertion compared to placebo. The PP-analysis 
showed a decrease in pain scores with IUD insertion. More participants receiving 
mepivacaine experienced insertion as easier than expected or as expected compared to 
placebo.  
Study III aimed to evaluate the effect of structured contraceptive counselling on LARC 
choice, LARC initiation and pregnancy rates in abortion clinics, maternal health clinics and 
youth clinics (paper III). It also aimed to evaluate user satisfaction of healthcare providers 
and patients with the intervention used and to characterize which providers and patients 
found the intervention most helpful (paper IV). The results show that more participants 
receiving structured contraceptive counselling chose LARCs compared to women receiving 
standard contraceptive counselling and that LARC initiation at 3 months follow-up was 
higher among women receiving structured contraceptive counselling. Both HCPs and 
participants reported high satisfaction with the intervention used in the trial. HCPs reported 
the use of the study intervention to be time neutral compared to standard contraceptive 
counselling. No individual identifiers of satisfaction could be determined among HCPs. 
More migrant and 2nd generation migrants than non-migrants found the educational video 
to be supportive in making their contraceptive choice.  
The study findings show that evidence-based contraceptive counselling focusing on method 
effectiveness is successful in increasing uptake of LARC, both when in need of EC and 
during regular contraceptive counselling. The findings suggest that women could have 
better experiences with IUD insertions if treated with intrauterine mepivacaine, which is 
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